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ABSTRACT OF DISSERTATION

TRICHLOROETHYLENE EXPOSURE AND TRAUMATIC BRAIN INJURY INTERACT
AND PRODUCE DUAL INJURY BASED PATHOLOGY AND PIOGLITAZONE
CAN ATTENUATE DEFICITS FOLLOWING TRAUMATIC BRAIN INJURY

The development of Parkinson's disease (PD) in humans has been linked to genetic and
environmental factors for many years. However, finding common single insults which can
produce pathology in humans has proved difficult. Exposure to trichloroethylene (TCE) or
traumatic brain injury (TBI) has been shown to be linked to PD and it has also been proposed
that multiple insults may be needed for disease development.
The present studies show that exposure to TCE prior to a TBI can result in pathology
similar to early PD and that the interaction of both insults is required for impairment in
behavioral function, and cell loss. Following exposure to TCE for 2 weeks there is a 75%
impairment in mitochondrial function but it has yet to be shown if the addition of a TBI can make
this worse. If the exposure to TCE is reduced to 1 week and combined with TBI a 50% reduction
in mitochondrial function is observed following the dual injury which requires both insults. These
studies provide further support for the hypothesis that PD may result from a multifactorial
mechanism.
It had been established that regional differences exist in mitochondrial function across
brain regions. The present studies indicate that previous findings are not likely to be the result of
differences in individual mitochondria isolated from the cortex, striatum, and hippocampus.
Further analysis of the effect of mitochondrial inhibitors on enzyme activity and oxygen
consumption reveal that the different regions of the brain are similarly affected by the inhibitors.
These results suggest that findings from previous studies indicating regionally specific deficits
following systemic toxin exposure, such as with TCE, are not the result of regional differences in
the individual mitochondria.
Given that TBI results in significant dysfunction, finding effective therapeutics for TBI will
provide substantial benefits to individuals suffering an insult. Treatment with Pioglitazone
following TBI reduced mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and

inflammation. These findings provide initial evidence that treatment with Pioglitazone may be an
effective intervention for TBI.
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Chapter 1
Introduction
Mitochondria
Normal physiological function:
The mitochondrion is a cellular organelle composed of two lipid bilayers, the
inner and outer mitochondrial membranes, and complex protein machinery necessary to
produce large amounts of adenosine-triphosphate (ATP), a required substrate for
numerous cellular functions. Historically, mitochondria were independent bacteria which
were incorporated into mammalian cells, leading to the ability for complex organisms to
develop (Lane, 2006). Prior to becoming part of the mammalian cell, the mitochondria
had a large genome containing thousands of genes (Timmis et al., 2004). Through many
years of evolution, mammalian mitochondria now only contain 37 genes and require
genes encoded in the nucleus for 99% of all mitochondrial proteins (Lane, 2006). The
production of ATP by the mitochondria requires electrons to be moved sequentially
through a series of proteins resulting in the generation of a proton gradient (Figure
1.1)(Nicholls and Ferguson, 2002). The inter-membrane space (IMS) lies between the
inner and outer mitochondrial membranes and protons are “pumped” here during
mitochondrial respiration. The process of moving protons from the matrix, the area inside
of the inner mitochondrial membrane, into the IMS utilizes energy from the flow of
electrons through the electron transport chain (ETC). As an electron moves through the
ETC, the energy level of the electron decreases as protons are pumped into the IMS
(Figure 1.2). In order for the mitochondria to obtain a high energy electron, food from the
diet is first broken down and metabolized into smaller molecules, such as glucose, which
can be further processed by the cell. The process of glycolysis converts
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Figure 1.1 Diagram of electron transport chain

The mitochondrial electron transport chain (ETC) utilizes high energy electrons to move
protons from the mitochondrial matrix into the intermembrane space. Electrons enter the
ETC through Complex I and Complex II as the result of the oxidation of NADH and
FADH 2 . Electrons move from Complexes I and II via Ubiquinone (CoQ10) to Complex III
and from Complex III to Complex IV via Cytochrome C. As electrons are transferred
through the ETC, protons are moved through Complexes I, III, and IV generating a
proton concentration gradient. The mitochondrial membrane potential, generated by the
concentration of protons in the intermembrane space, is utilized by Complex V to
generate ATP.

Figure 1.2: Diagram of decrease in electron energy level

The proteins of the mitochondrial electron
transport chain (ETC) have different redox
potentials which range from ~-300mV at
Complex I to ~600mV at Complex V. The
sequential change in redox potential facilitates
the directional flow of electrons through the
ETC. As the electrons are moved through the
ETC, the energy state of the electron is reduced
significantly as a result of the usage of energy to
translocate protons from the mitochondrial
matrix to the intermembrane space
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glucose into pyruvate through a process of ten enzymatic steps. Pyruvate can be further
processed in the mitochondrial matrix by the tricarboxylic acid cycle (TCA cycle) in order
to produce NADH and FADH 2 . Complex I (NADH-Ubiquinone Oxidoreductase) can
oxidize NADH to NAD+ by transferring an electron from NADH to an iron-sulphur (Fe-S)
center which resides in Complex I. This first electron transfer results in the movement of
protons into the IMS. Complex II (Succinate Dehydrogenase) can oxidize the FADH 2
produced by the TCA cycle into FAD in a similar manner to the oxidation of NADH by
Complex I. Even though Complex II does receive an electron from FADH 2 no proton
translocation to the IMS occurs during this step. Both Complexes I and II can then
transfer the electron obtained from either NADH or FADH 2 to Complex III via ubiquinone
(Coenzyme Q10), which resides in the IMS. Complex III can subsequently transfer the
electron to Cytochrome C and move additional protons into the IMS. Cytochrome C then
transfers the electron to Complex IV (Cytochrome C Oxidase), which is able to utilize
energy from the electron to move an additional four protons into the IMS while
consuming oxygen in the form of O 2 . The consumption of oxygen by Complex IV results
in the formation of two molecules of water and the elimination of four electrons. The
process by which electrons move through the ETC from complex to complex while
“pumping” protons into the IMS results in the formation of a mitochondrial membrane
potential (ΔΨ). As a result of the generated ΔΨ, Complex V (ATP Synthase) is able
harness the energy in the proton gradient by allowing protons to flow down the proton
concentration gradient and through Complex V, resulting in the production of ATP. The
mitochondrial respiratory process is vital to normal cellular function and survival and
even transient inhibition of the process can lead to a loss of ATP and cell death.
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Regional differences in basal mitochondrial function:
Given the diversity of the nervous system and the regional differences observed
in mitochondrial function in different experimental models, it is currently understood that
regional differences play an important role in mitochondrial function (for review see
(Dubinsky, 2009)). As with many other aspects of cellular function, calcium plays an
important role in mitochondrial function. Regional differences in the levels and regulation
of calcium can directly affect the function of the mitochondria. In response to increases
in intracellular calcium levels, the aspartate-glutamate carrier becomes activated and
imports NADH (Pardo et al., 2006). The increased intracellular concentration of NADH is
thought to underlie the observed increases in activities of the α-ketoglutarate, Pyruvate,
and oxoglutarate dehydrogenases following increases in intracellular calcium (Denton et
al., 1988). In addition to calcium induced changes in the activities of some of the
dehydrogenases,

regional

differences

have

also

been

observed

for

Malate

dehydrogenase and creatine kinase (Ryder, 1980, Gupta et al., 2000). In addition basal
differences, neuronal activity has been shown to transcriptionally regulate mitochondrial
subunit expression (Wong-Riley et al., 1997). Reducing neuronal activity with the
application of tetrodotoxin has been shown to result in a loss of Cytochrome C oxidase
levels (Nie and Wong-Riley, 1996), further indicating a close relationship between levels
of neuronal activity and mitochondrial function. An additional difference in mitochondrial
function between different regions of the brain can be observed by comparing spare
respiratory capacity, which is the ability for mitochondria to increase the respiratory rate.
Fern compiled data from many sources in order to compare the amount of spare
respiratory capacity across brain regions and across mitochondrial complexes. It was
observed that regions of the brain such as the striatum, which are highly metabolically
active, have relatively lower levels of spare respiratory capacity (Fern, 2003), indicating
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that even though mitochondrial subunit levels are correlated with neuronal activity there
may be an upper limit to the amount of mitochondrial function for a given brain region.
One of the most striking findings from Fern’s analysis is that the regions with the lowest
spare respiratory capacity for a given mitochondrial complex are also the regions of the
brain which are the most susceptible to mitochondrial inhibitors which block that
complex. The striatum was the next to lowest region of the brain with regards to
Complex II spare respiratory capacity (Fern, 2003) and this is also a region of the brain
highly susceptible to the Complex II inhibitor 3-Nitropropionic acid (Beal et al., 1993).
Further evidence supporting the existence of regional differences in brain mitochondria
comes from work looking at the response of mitochondria to ischemic insults. Following
a 30 minute ischemic event and six hours of reperfusion the paramedian cortex exhibited
no decrease in mitochondrial function while the dorsal-lateral striatum exhibited
approximately a 25% decrease in mitochondrial state 3 function (Sims, 1991), further
indicating that the striatum is more susceptible to bioenergetic inhibition.
Synaptic vs. non-synaptic mitochondrial function:
In addition to different regions of the brain exhibiting differences in mitochondrial
function, differences have been observed between synaptic and non-synaptic
mitochondria from the same region of the brain (Davey et al., 1997, Brown et al., 2006,
Naga et al., 2007, Pathak and Davey, 2008). By using inhibitors specific for Complexes
I, III, and IV the susceptibility of synaptic and non-synaptic mitochondria to mitochondrial
inhibition has been investigated. Synaptic mitochondria isolated from the whole brain are
markedly more susceptible to Complex I inhibition by rotenone than non-synaptic
mitochondria (Pathak and Davey, 2008). Non-synaptic mitochondria required a 72%
inhibition of Complex I before any changes were observed in mitochondrial oxygen
consumption while synaptic mitochondria began showing mitochondrial respiration
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deficits after only 25% inhibition of Complex I (Pathak and Davey, 2008). In contrast to
the large differences between synaptic and non-synaptic mitochondria with regards to
Complex I inhibition and mitochondrial oxygen consumption, no major differences are
observed between Complex III and Complex IV inhibition and mitochondria oxygen
consumption with tissue isolated from the whole brain (Pathak and Davey, 2008). When
looking within sub-regions of the brain, the cortex and CA1 region of the hippocampus
exhibit similar effects of Complex I inhibition with both regions showing that synaptic
mitochondria show oxygen consumption deficits with only 25% inhibition of Complex I
while non-synaptic mitochondria require 60% inhibition (Pathak and Davey, 2008). In
addition to being more susceptible to mitochondrial Complex I inhibition, synaptic
mitochondria have also been shown to regulate calcium differently than non-synaptic
mitochondria (Brown et al., 2006, Naga et al., 2007). Synaptic mitochondria isolated
from cortical tissue are not able to buffer as much calcium as non-synaptic mitochondria
before undergoing mitochondrial permeability transition pore (mPTP) formation (Brown
et al., 2006). Even the addition of Cyclosporine A, which can inhibit the formation of the
mPTP, cannot raise the calcium buffering capacity of synaptic mitochondria up to that of
basal non-synaptic mitochondria (Brown et al., 2006). Further evidence shows that the
major underlying difference between synaptic and non-synaptic mitochondrial calcium
buffering capacity resides in the significantly higher levels of Cyclophilin D in synaptic
mitochondria (Naga et al., 2007). Removing Cyclophilin D from synaptic mitochondria by
utilizing knockout mice results in an increase in the calcium buffering capacity of the
synaptic mitochondria to that of wild-type non-synaptic mitochondria (Naga et al., 2007).
The collection of findings looking at synaptic and non-synaptic mitochondria further
defines the significance of regional differences in mitochondrial function since not only
are there differences among mitochondria from different areas of the brain but there are
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differences in mitochondria between different portions of the cellular architecture of a
given brain region, specifically synaptic and non-synaptic regions.
Regional mitochondrial differences following systemic toxin exposure:
An important aspect of regionally specific mitochondrial differences can be
observed following the systemic administration of mitochondrial toxins, where specific
regions of the brain are more affected by a given toxin. The toxins 3-nitropropionic acid
(3-NP), cyanide, and trichloroethylene (TCE) have all been shown to inhibit
mitochondrial function and produce regionally specific damage following systemic
administration (Hicks, 1950, Beal et al., 1993, Gash et al., 2008, Liu et al., 2010). The
toxin 3-NP irreversibly inhibits Complex II (succinate dehydrogenase)

of the

mitochondrial electron transport chain (Alston et al., 1977) and systemic exposure to 3NP produces an excitotoxic lesion in the striatum but not in other regions of the brain
(Beal et al., 1993). Regional differences in how the mitochondria are affected and
regulated following exposure to 3-NP may underlie the observed regionally specific
susceptibility to 3-NP. Following exposure to 3-NP, striatal neurons but not cortical
neurons up regulate Cytochrome-C oxidase (COX) levels which results in increases in
ATP levels with the side effect of increased peroxide production, leading to increases in
oxidative stress (Singh et al., 2010). Additionally, the striatum has been shown to have
one of the lowest spare respiratory capacities for Complex II of any brain region
accessed (Fern, 2003) and this may drive a proportionally higher degree of energy
impairment in the striatum following exposure to 3-NP. With a lower basal spare
respiratory capacity, mitochondrial inhibition by 3-NP likely drives the striatum to up
regulate COX in an attempt to maintain ATP production and cell viability. Even though
the increase in COX leads to more ATP production, the increased peroxide production
would make the cells more vulnerable and play a role in the cell loss observed in the
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striatum (Singh et al., 2010). Similar to 3-NP, TCE has been shown to produce regionally
specific deficits following systemic administration (Gash et al., 2008, Liu et al., 2010).
Following six weeks of TCE exposure in rats, mitochondrial bioenergetic impairment was
observed in the substantia nigra but not in the striatum or liver (Gash et al., 2008). At
both two and six weeks following exposure to TCE there are increases in markers of
oxidative stress in the substantia nigra along with significant impairment in mitochondrial
Complex I activity (Liu et al., 2010). In the striatum there is an increase in Complex I
activity following six weeks of TCE exposure (Gash et al., 2008) and this may represent
a compensatory response similar to the striatal increase in COX following 3-NP
exposure (Singh et al., 2010). In addition to predominately affecting mitochondria
bioenergetic function in the substantia nigra after six weeks of exposure, TCE also
results in death of dopaminergic neurons but not cholinergic or GABAergic neurons (Liu
et al., 2010), further expanding the level of complexity in regional mitochondrial deficits
to including cell type specific responses. Cyanide, a mitochondrial Complex IV inhibitor,
has also been shown to produce regionally specific damage, most notably to white
matter (Hicks, 1950), and like 3-NP its toxicity is correlated the amount of spare
respiratory capacity for the region it affects (Fern, 2003). Exposure to cyanide does
affect mitochondrial functions in other regions, such as the cortex where reductions in
COX activity and ATP levels are observed shortly after exposure (MacMillan, 1989),
however, the long term damage still remains mainly in the white matter of the corpus
callosum following sub lethal exposure (Brierley et al., 1976). The major apparent
similarity observed with the different toxin models is that pathology tends to follow basal
differences in mitochondrial function and regional requirements for energy sources.
Regions which have lower levels of spare mitochondrial respiratory capacity for a given
mitochondrial complex are more likely to show damage following exposure to a toxin
inhibiting that complex. Additionally, cell populations with high energy demands, such as
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dopamine neurons, are more susceptible to inhibition of mitochondrial function than
other cell types from the same brain region (Zeevalk et al., 1997). Brain regions which
cannot maintain sufficient mitochondrial function and ATP production can become
damaged and undergo cell loss while regions which can maintain sufficient energy
production survive.
Pathological mitochondrial function:
The complexity of the electron transport chain process leaves the system
vulnerable to many insults and disturbances. For example, following TBI an ischemic
insult can result in a loss of oxygen needed by the mitochondria at Complex IV to
remove electrons from the ETC. Following reperfusion of the hypoxic tissue with
oxygenated blood there is a rapid increase in the production of reactive oxygen species
(ROS) which can overcome endogenous antioxidant systems and lead to further
damage and dysfunction (for review see (Sugawara and Chan, 2003)). Given its critical
role in normal cellular function by producing ATP, the mitochondria's susceptibility to a
wide range of inhibitors and insults, and its ability to initiate cell death cascades, it is not
surprising that the mitochondria has been found to play an important role in numerous
pathological conditions. Mitochondrial dysfunction has been observed following TBI or
exposure to environmental toxins such as TCE as well as in degenerative neurological
conditions such as Parkinson's disease (PD). The role the mitochondria plays in these
separate yet related pathologies is discussed in more detail in the sections specific to
each insult/pathology.
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Traumatic brain injury
Epidemiology:
Every year in the United States there are approximately 1.7million individuals that
obtain medical care at a hospital emergency department (ED) for treatment related to a
traumatic brain injury (TBI) (Faul et al., 2010). Of the individuals that go to an ED for
care related to a TBI, approximately 52,000 die, 275,00 become hospitalized, and 1.36
million are released (Faul et al., 2010). The level of severity for a TBI can vary
significantly between individuals with some people sustaining a mild TBI with short term
alterations in cognition and mental status to individuals having a severe TBI which
results in chronic long term disability and impairment. Current estimates predict that in
the United States there are approximately 5.3 million individuals living with prolonged
deficits due to a TBI (Thurman et al., 1999). The prolonged impairments from a TBI can
affect multiple aspects of normal daily function including cognition, sensorimotor
function, language, and emotion (NINDS, 2002). The four most common causes of TBI
are falls (28%), motor vehicle accidents (20%), impact with an object (19%), and
assaults (11%) (Figure 1.3)(Langlois et al., 2006). Not only does TBI impart significant
hardships on the individual sustaining the injury but it is also estimated that in the United
States alone TBIs cost $60 billion annually as a result of medical expenses and lost
productivity (Finkelstein et al., 2006). The incidence of TBI can vary widely between
gender, ethnic, and age groups, and men are twice as likely as women to sustain a TBI
(Langlois et al., 2006). On average people over the age of 75 are more likely to die from
a TBI and African Americans have the highest likelihood of death compared to other
ethnic backgrounds (Langlois et al., 2006). The primary cause of a TBI can vary widely
and plays a direct and important role in the pathology which ensues.
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Figure 1.3: Causes of traumatic brain injury

Traumatic brain injury (TBI) results from various different causes. The most common
mechanisms leading to TBI pathology are falls, motor vehicle accidents, impact with an
object, and assaults. These four causes are responsible for 78% of all TBIs in the United
States.

Primary injury mechanisms:
TBI pathology results from both a primary injury and a secondary injury cascade.
The primary injury is due to biomechanical damage which results in the shearing and
compression of neuronal, glial, and vascular tissue. TBIs can result from numerous
different causes (Figure 1.3), present with a variety of different anatomical pathologies,
and present with injury levels ranging from mild to severe. Current research on human
TBI has generally utilized neurological injury severity criteria to classify the severity of
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the injury (Narayan et al., 2002, Saatman et al., 2008) with the 15-point Glasgow Coma
Score (GCS) (Teasdale and Jennett, 1974) being the most common (Narayan et al.,
2002). Though the GCS has been utilized extensively for clinical trials seeking to enroll
patients with severe TBIs, the GCS does not work well for certain populations such as
infants, it does not distinguish less severe injuries, and it cannot distinguish the
underlying type of injury (Saatman et al., 2008). Beyond determining the severity of a
TBI, it is important to understand the causative mechanism of the injury since different
types of injuries require different medical care and have different long term outcomes.
TBI can result in various neuroanatomical changes which include epidural hematoma,
parenchymal hematoma, diffuse axonal injury (DAI), subdural hematoma, subarachnoid
hemorrhage, intraventricular hemorrhage, and diffuse brain swelling (Saatman et al.,
2008). Of the various primary injuries, the four main pathologies observed in human TBI
are subarachnoid hemorrhage, DAI, contusion, and hematoma (Saatman et al., 2008).
Patients can present with any combination of pathoanitomical changes or even just a
single injury type. It was recently shown that patients presenting with an initial GCS <8,
indicating a severe TBI, can exhibit single injury types which cannot be distinguished by
the GCS score (Saatman et al., 2008). The problems associated with utilizing a GCS
score for patient treatment decisions indicates that new strategies for rapidly classifying
injury type need to be found since the type of injury affects patient outcome (Gennarelli
et al., 1982). Given the variety of types of injuries, it is crucial to understand what type of
injury a patient has so that appropriate medical care can be given.
Secondary injury mechanisms:
The cascade of secondary injury damage, which occurs in the hours and days
following the initial insult, is due to activation of pathophysiological cascades, consisting
of complex biochemical and cellular pathways that influence progression of the injury.
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Secondary injury processes include alterations in excitatory amino acids (Yamamoto et
al., 1999, Rose et al., 2002), increased reactive oxygen species (ROS) production
(Marklund et al., 2001, Hall et al., 2004, Tavazzi et al., 2005), disruption of calcium
homeostasis (Mattson and Scheff, 1994, Xiong et al., 1997, Sullivan et al., 1999c), posttraumatic neuroinflammation (Morganti-Kossmann et al., 2001, Vlodavsky et al., 2006)
and mitochondrial dysfunction (Azbill et al., 1997, Xiong et al., 1997, Sullivan et al.,
1998b, Sullivan et al., 1999a, Sullivan et al., 1999b). As a result of these secondary
injury processes, there are significant reductions in ATP levels (Sullivan et al., 1998a),
increases in lipid peroxidation (Sullivan et al., 1998a), release of Cytochrome C (Sullivan
et al., 2002) and activation of apoptotic pathways (Sullivan et al., 2002), all of which can
lead to the initiation of cell death pathways.
Mitochondrial dysfunction following traumatic brain injury:
Mitochondria are a major component of this secondary injury pathway because
they function as a highly sensitive regulator of cell death mechanisms and as the primary
energy producer for the cell. The mitochondria play a pivotal role in cerebral energy
metabolism, intracellular calcium homeostasis, and ROS generation and detoxification.
Following TBI, a significant disruption of mitochondrial homeostasis has been
documented that results in a decline in cellular bioenergetics, increased mitochondrial
ROS production and a decline in synaptic equilibrium (Azbill et al., 1997, Xiong et al.,
1997, Sullivan et al., 1998b, Sullivan et al., 1999a, Sullivan et al., 1999b). Immediately
after the TBI reductions in the amount of ATP have been observed in the cortex
following a cortical impact brain injury and this impairment in mitochondrial function
precedes increases in levels of lipid peroxidation which begin to increase by 30 minutes
post injury (Sullivan et al., 1998b).
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Looking at more detailed mechanisms of the mitochondrial dysfunction which occurs
after TBI has revealed that in cortical synaptosomes isolated 30 minutes after the injury
there is a loss of mitochondrial membrane potential, increases in intracellular
mitochondrial calcium loading, increased susceptibility to calcium induced mitochondrial
permeability transition, and increases in the production of ROS (Sullivan et al., 1999c).
The mitochondrial deficits which occur after the injury can lead to both mitochondrial and
cellular damage and dysfunction. The loss of the mitochondria’s ability to produce ATP
can impair the cell’s ability to maintain both normal and post-injury functions and
ultimately lead to cell death (Nicholls and Budd, 2000). Additionally, factors such as
mitochondrial ROS production and increases in levels of mitochondrial lipid peroxidation
can result in mitochondrial bioenergetic impairments resulting in further reductions in
mitochondrial dependent ATP production as well as the induction of mitochondrial
dependent cell death pathways (Nicholls and Budd, 2000). Considering the multiple
mechanisms of mitochondrial dysfunction that occur following TBI, the degree of
mitochondrial injury or dysfunction can be an important determinant of cell survival or
death (for reviews see (Robertson, 2004, Sullivan et al., 2005, Robertson et al., 2006)
and it has been shown that therapeutic treatments designed to protect and stabilize the
mitochondria have the ability to reduce injury in preclinical studies (Sullivan et al., 2000a,
Pandya et al., 2007).
Mitochondrial treatments for traumatic brain injury:
Given the important role which the mitochondria play in both normal and post-TBI
pathology,

and the desire to find therapeutic

interventions

which result

in

neuroprotection, drugs targeting mitochondrial function have been pursued as potential
effective interventions.

Mitochondrial therapeutics which have been pirsued for the

treatment of TBI include Cyclosporine A (CsA), mitochondrial uncouplers such as 2,4-
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Dinitrophenol (2,4-DNP) and FCCP, as well as alternative energy sources for the
mitochondria.
Cyclosporin A is an immunosuppressive drug which is capable of binding to
mitochondrial Cyclophilin D thereby inhibiting the formation of mitochondrial permeability
transition pore (mPTP) (Broekemeier et al., 1989, Broekemeier and Pfeiffer, 1995).
Following TBI there is significant mitochondrial dysfunction which occurs acutely after
the injury (Sullivan et al., 1998b, Sullivan et al., 1999c, Sullivan et al., 2004). Treatment
with CsA 15 minutes after a TBI has shown the ability to ameliorate multiple aspects of
mitochondrial pathology by preventing the formation of the mPTP, preserving membrane
potential, reducing mitochondrial calcium accumulation, and reducing the production of
mitochondrial ROS (Sullivan et al., 1999c). It has also been observed that treatment with
CsA is capable of reducing the amount of cortical tissue loss by up to 50% following a
single bolus injection (Sullivan et al., 1999c) and up to 74% following a continuous
infusion of CsA (Sullivan et al., 2000c). Further work has indicated that significant
mitochondrial improvements can still be obtained even if treatment with CsA is delayed
for 24 hours following the injury (Sullivan et al., 2000b), which should provide a large
therapeutic window of opportunity for the usage of CsA in humans. Confirming the
mitochondrial findings observed with CsA treatment, administration of the nonimmunosuppressive CsA analog NIM811 was shown to protect the mitochondria
following TBI (Mbye et al., 2008). Treatment with NIM811 resulted in preservation of the
mitochondrial respiratory control ratio (RCR), mitochondrial bioenergetic function, and
prevented increases in the oxidative damage markers 4-hydroxynonenol (4-HNE) and 3Nitrotyrosine (3-NT) (Mbye et al., 2008). Given the effectiveness of CsA in preclinical
research, the clinical testing of CsA in humans for the treatment of TBI has begun
(Hatton et al., 2008, Mazzeo et al., 2009).
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A second therapeutic intervention targeting the mitochondria is the use of
chemical mitochondrial uncouplers. Mitochondrial uncoupling is a process by which
protons are moved from the mitochondrial intermembrane space to the matrix without
going through Complex-V of the mitochondria, thereby rapidly reducing mitochondrial
membrane potential (for review see (Sullivan et al., 2004, Mattiasson and Sullivan,
2006)). Given that after TBI there is a rapid increase in excitotoxicity which results in
intracellular calcium accumulation (Fiskum, 2000) it was proposed that this calcium
accumulation would lead to mitochondrial calcium overload (Pandya et al., 2007). The
hypothesis was generated that treatment with mitochondrial uncouplers would reduce
the mitochondrial calcium overload since the mitochondrial accumulation of calcium is
membrane potential dependent (Pandya et al., 2007). A single intraperitoneal injection of
either 2,4-DNP or FCCP five minutes after a TBI led to reductions in the amount of
cortical tissue loss and hippocampal Fluoro Jade-B positive neurons, and this was
correlated with preservations in cognitive function (Pandya et al., 2007). As was
hypothesized, animals treated with mitochondrial uncouplers exhibited preserved levels
of mitochondrial bioenergetic function, reductions in in situ calcium loading, and
reductions in mitochondrial ROS production (Pandya et al., 2007). Given that a five
minute post-injury treatment time is not feasible for translating to human usage, a
delayed time course for administration was tested (Pandya et al., 2009). Delaying the
administration of the mitochondrial uncoupler FCCP up to six hours after the injury
produced the same beneficial effect as observed following a five minute post-injury
injection, indicating a broad therapeutic window of opportunity for the treatment of TBI
with a mitochondrial uncoupler (Pandya et al., 2009).
Additional work has pursued the use of alternative energy sources for the
mitochondria following TBI to maintain ATP levels. Following either a moderate or
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severe TBI, alterations in the brain’s usage of oxygen, glucose, and lactate have been
observed in humans which suggests the brain changes how it utilizes energy sources for
the production of ATP (Glenn et al., 2003). Given that the brain changes how it
generates ATP after a TBI, it was proposed by Prins et al. that administration of the
ketone beta-hydroxybutarate(B-HB) after TBI would ameliorate energy deficits observed
after the injury (Prins et al., 2004). Following a three hour infusion of B-HB beginning
immediately after the injury, treatment prevented the 20% reduction in ATP levels which
was observed in vehicle-treated injured animals (Prins et al., 2004). It was also observed
that sham animals did not exhibit an increase in cerebral uptake of B-HB, which was
observed in the injured animals, further suggesting that the TBI directly alters how the
brain responds to mitochondrial energy sources and what fuel sources the brain utilizes
after a TBI (Prins et al., 2004).
Supporting

the

concept

that

alternative

energy

sources

can

lead

to

neuroprotection after TBI, research has shown that post-injury fasting promotes
neuroprotection by reducing cortical tissue loss, reducing mitochondrial calcium loading,
maintaining mitochondrial bioenergetic function, and preventing increases in oxidative
damage (Davis et al., 2008). Given that fasting increases both insulin and ketone levels
in the blood, both were testing following TBI to determine if either component of postinjury fasting was responsible for the neuroprotection. Davis et al. showed that the
ketone B-HB but not insulin was capable of increasing tissue sparing after the injury
(Davis et al., 2008), providing further evidence and support that following TBI providing
the brain with alternative fuels, specifically the ketone B-HB, is capable of providing
neuroprotection and reducing post injury deficits.
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Excitotoxicity following traumatic brain injury:
The concept of excitotoxicity was developed by Olney after subcutaneous
injections of monosodium glutamate were shown to produce neuronal loss in various
brain regions (Olney, 1969). The mechanism of cell death resulting from glutamate
exposure has been shown to result from the influx of calcium into the cell (Choi, 1987)
and that the NDMA receptor but not voltage-sensitive calcium channels are the cytotoxic
source of the calcium (Tymianski et al., 1993). It has been shown that the link between
NMDA receptor activation and the resulting mitochondrial dysfunction results from their
close proximity to each other (Peng and Greenamyre, 1998) and this connection results
in the mitochondria being considered the primary cause of excitotoxic cell death
(Fiskum, 2000). A major mechanism underlying glutamate induced damage is through
the effects of calcium influx on the mitochondria and damage to calcium extrusion
pathways, which inhibit mitochondrial bioenergetic function (Ward et al., 2000). Both
aspects of mitochondrial impairment can eventually lead to cellular deregulation of
calcium and the loss of ATP production (Figure 1.4) (Ward et al., 2000). It has further
been shown that the increase in mitochondrial calcium concentrations is mitochondrial
membrane potential dependent. Treatment with mitochondrial uncouplers can reduce
the accumulation of calcium in the mitochondria following TBI (Pandya et al., 2009).
TBI in humans has been shown to lead to elevations in the levels of excitatory
amino acids (EAAs), specifically the neurotransmitter glutamate, in cerebrospinal fluid
(CSF) (Bullock et al., 1998, Koura et al., 1998, Yamamoto et al., 1999). Patients with
elevated CSF glutamate levels have been shown to have increased post-injury
intracranial pressure and a worse outcome six months after the injury (Koura et al.,
1998). Animal models of TBI have shown that the increases in glutamate levels are
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Figure 1.4: Excitotoxic calcium induced mitochondrial death

Following TBI, the cascade of excitotoxic damage leads to both cell death and damage
to neighboring cells. As a result of glutamate activation of the NMDA receptor, calcium
enters the cell and accumulates in the mitochondria. The mitochondrial accumulation of
calcium can lead to either necrotic or apoptotic cell death. Both cell death pathways can
result in the further release of calcium which can perpetuate the process.

linked to injury severity with moderately injured animals showing a 282% increase in
glutamate and severely injured animals showing a 940% increase when compared to
sham animals (Faden et al., 1989). Even though glutamate levels have been shown to
increase after injury and be correlated with a worse outcome, simply showing post-injury
increases in EAA levels is not sufficient to show that these changes directly play a role in
increased pathology. To determine whether the increased levels of EAAs play a direct
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role in outcome and pathology, various NMDA receptor antagonists have been utilized to
prevent the activation of the NMDA receptor by glutamate (Faden et al., 1989, Shapira et
al., 1990). Following a fluid percussion injury paradigm, administration of NDMA receptor
antagonists have shown the ability to improve motor function and bioenergetic status
(Faden et al., 1989) and reduce brain damage and edema (Shapira 1990). Even with the
success of NMDA antagonists in animals models of TBI, attempts to move compounds
into clinical usage has been met with much difficulty (for review see (Ikonomidou and
Turski, 2002)). The usage of NMDA antagonists in humans has been linked to possible
neurological damage (Davis et al., 2000) and animal models suggest NMDA antagonists
may have a short and potentially unusable therapeutic window of efficacy in humans
(Meldrum, 1990).

Even though the clinical usage NMDA antagonists to block

excitotoxicity has not reached success as a treatment for brain injuries in humans, the
mechanisms by which glutamate induced excitotoxicity leads to neuronal death is widely
accepted.
Mitochondrial permeability transition pore:
A downstream outcome from increases in mitochondrial calcium loading, such as
from excitotoxicity, is the formation of the mitochondrial permeability transition pore
(mPTP) (Sullivan et al., 2000c, Sullivan et al., 2005). The mPTP is a multi-protein
complex which consists of the adenine nucleotide translocase (ANT), the voltagedependent anion channel (VDAC), and Cyclophilin D (Baines, 2009). The proteins which
form the mPTP can be found both in the inner and outer mitochondrial membranes
which allows for the efflux of substances from the IMS and matrix into the cytosol when
the pore opens. Cytochrome C, endonuclease G, and apoptosis inducing factor (AIF) are
three important substances released after the opening of the mPTP since their release
from the mitochondria can lead to the activation of cell death cascades. Endonuclease
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G and AIF play an important role during apoptosis since they can initiate controlled DNA
degradation. When Cytochrome C is released into the cytosol it is capable of interacting
which the cytosolic protein Apaf-1 and form the apoptosome. The apoptosome recruits
procaspase-9 and initiates the activation of caspases, such as Caspase-3, which drive
the characteristic protein degradation observed with apoptosis. Therapeutic intervention
with Cyclosporin A (CsA) can delay the opening of the mPTP and this intervention has
been shown to have a beneficial effect in experimental models of TBI (Scheff and
Sullivan, 1999, Sullivan et al., 1999c, Sullivan et al., 2000b, Sullivan et al., 2000c).
Similar to excitotoxic mechanisms of cellular injury after TBI, intervening rapidly after a
TBI in order to prevent the opening of the mPTP is critical to prevent the initiation the cell
death cascades.
Traumatic brain Injury induced changes in the dopaminergic system:
The dopaminergic (DA) neurons in the brain influence numerous functions
including cognition, movement, and emotion (for reviews see (Jackson and WestlindDanielsson, 1994, Floresco and Magyar, 2006)). Dopamine neurons which originate in
the substantia nigra (SN) send the majority of their projections into the striatum (ST) ,
however, axons also extend into the cortex and hippocampus as well (for review see
(Van den Heuvel and Pasterkamp, 2008)). The DA fibers which project from the SN to
the ST modulate the function of the basal ganglia (BG) by activating both D1 and D2
dopamine receptors (Graybiel, 2000). The D1 and D2 receptors differ greatly in protein
structure (Jackson and Westlind-Danielsson, 1994) and it is currently thought that
activation of the D1 receptor serves to excite the direct pathway of the BG while
activation of the D2 receptor functions to inhibit the indirect pathway (Graybiel, 2000).
The summation of all of the interconnections within the BG culminates at the thalamus
and results in a single refined signal being sent to the cortex.
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Following TBI, alterations in the DA system have been shown to occur and these
changes are thought to underlie many of the deficits observed after TBI (for review see
(Bales et al., 2009)). In humans, Donnemiller showed that following a severe TBI, where
the average GCS was 5.8±4.2, patients exhibited alterations in both the dopamine
transporter (DAT) and the D2 receptor (Donnemiller et al., 2000). Compared to controls,
individuals which sustained a severe TBI had a loss of 55% of the DAT binding and 27%
loss of D2R binding, however, the overall degree of change in Striatal DAT or D2R was
not correlated with the severity of the TBI (Donnemiller et al., 2000). The lack of a direct
correlation between TBI severity and the amount of change in the DA system indicates
that even though TBI can produce DA deficits, since the GCS does not specifically
measure DA function it cannot be used to predict the amount of DA dysfunction. Similar
to what has been observed in humans, in a rodent model of severe TBI a 40% reduction
in the levels of the DAT have been observed in the striatum 14 days after the injury
(Wagner 2005). In these same animals, striatal evoked dopamine release was
significantly reduced in injured animals ipsilateral to the injury and the V max for dopamine
clearance was only 52.1% of naïve controls (Wagner et al., 2005).
Further evidence supporting a role for the DA system after TBI comes from the
success of using the DA reuptake inhibitor methylphenidate as a treatment for cognitive
and motor dysfunction after injury (Kaelin et al., 1996, Plenger et al., 1996, Whyte et al.,
1997). Plenger et al. showed in a double-blind placebo controlled study that at 30 days
following subacute treatment with methylphenidate patients receiving the drug exhibited
improvements in attention and motor function (Plenger et al., 1996). In another clinical
trial, Whyte et al. showed that individuals who sustained a severe TBI showed significant
improvements in information processing, attentiveness during individual work tasks, and
caregiver ratings of attention (Whyte et al., 1997). Both of these reports only provided
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indirect evidence of alterations in the DA system after TBI since the clinical trial studies
only showed that the drug lead to improvements in function and not that there were
deficits in DA system. It wasn’t until studies such as those conducted by Donnemiller et
al. which showed changes in the DAT and D2R that evidence existed to show TBI
dependent changes in the DA system. In order to elucidate how treatment with
methylphenidate might be affecting function after TBI, Wagner et al. utilized a rodent
model of severe TBI to look at the effects of methylphenidate on striatal dopamine
function. After only a single injection of methylphenidate, injured animals did exhibit an
increase in the amount of striatal evoked dopamine, however, the increase was not as
high as what was observed in sham animals treated with a single dose of
methylphenidate (Wagner et al., 2009), indicating that the injured brain responds
differently to DA agonists. When the treatment regimen of methylphenidate was
extended for two weeks, animals which received a severe TBI and treatment with
methylphenidate exhibited both an increase in the total rate and amount of dopamine
release in the striatum and these changes resulted in evoked dopamine levels similar to
sham animals (Wagner et al., 2009). The results from the animal studies utilizing
methylphenidate treatment after TBI show that injury does result in reductions in
dopamine levels and that treatment with a DA agonist can reverse these changes if the
drug is given long enough. Results from the animal studies further support what was
observed in humans by Plenger et al. where stopping methylphenidate treatment
resulted in the loss of a difference between drug and placebo groups (Plenger et al.,
1996). When methylphenidate is allowed to wear off the increases in evoked dopamine
release return to post-injury levels (Wagner et al., 2009). The human and rodent data
suggest that following TBI the DA systems in the brain, especially in the striatum,
become compromised and do not function adequately for normal function. Administration
of a dopamine agonist, such as methylphenidate, is capable of overcoming some of the
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deficits in the DA system and improving function, however, it does not lead to permanent
changes.
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Parkinson’s disease:
Epidemiology:
Parkinson’s Disease (PD) is a neurodegenerative disorder characterized by the
symptoms: tremor, rigidity, bradykinesia, hypokinesia, akinesia, and postural instability
(Marsden, 1994), which result from the loss of dopaminergic (DA) neurons within the
substantia nigra. PD generally affects individuals after age 65 and in the United States it
is estimated that 60,000 new cases are diagnosed each year leading to a total of 1.5
million people currently suffering with the neurological dysfunction which characterizes
the disease. The motor impairment found in patients suffering with PD occurs in a
progressive manner and worsens with time. The loss of DA input into the striatum from
the substantia nigra is the major neurological cause of the motor dysfunction (Marsden,
1994) and human evidence suggests that loss of the majority of DA neurons in the
substantia nigra must occur before motor dysfunction becomes apparent (Riederer and
Wuketich, 1976, Morrish et al., 1996). Since Dr. James Parkinson first described the
pathology of PD in his essay on “Shaking Palsy” (Parkinson, 2002), no definitive cause
has been found which describes the etiology for all cases of sporadic PD.
Anatomical circuitry of the basal ganglia:
The basal ganglia (BG) is a collection of brain nuclei which includes the striatum,
globus pallidus, subthalamic nucleus (STN), and substantia nigra. The BG plays
important roles in motor, associative, and limbic functions within the brain (Alexander et
al., 1986, Middleton and Strick, 2000). DA projections from the substantia nigra
innervate D1 and D2 receptors in the striatum and influence the interconnections
between the remaining regions of the BG, which are interconnected by inhibitory
GABAergic and excitatory glutamatergic fibers (Figure 1.5) (Graybiel, 2000) . The effect
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of the BG circuitry on motor control is the most understood of its functions (Obeso et al.,
2008) and lesions in the STN and substantia nigra result in frequently characterized
motor dysfunctions in humans. The arrangement of the neuronal connections within the
BG are somatotopically organized (Takada et al., 1998) with the regions controlling
motor function residing dorsolaterally (DeLong and Coyle, 1979). The substantia nigra
impacts the function of the BG by exciting D1 neurons of the direct pathway and
inhibiting D2 neurons from the indirect pathway (Figure 1.5) (Graybiel, 2000). The
activities of the direct and indirect pathways result in the regulation of the amount of
inhibition on the thalamus,

thereby modulating motor control through the thalamo-

cortical projections (Graybiel, 2000).
Figure 1.5: Basal ganglia circuitry
The normal circuitry of the basal ganglia (BG) involves interconnections between
dopaminergic (DA), glutamatergic (Glu), and GABAergic (GABA) fibers. The regions of
the BG are interconnected in such a
way that allows for the control of
thalamic activity and ultimately
thalamic modulation of cortical
function. In Parkinson's disease, the
DA neurons in the substantia nigra
are lost resulting in a loss of
nigrastriatal DA input. The loss of
nigral input into the striatum ultimately
results in an increase in the inhibitory
GABAergic single into the thalamus.
The resulting inhibition of the
thalamus leads to a decrease in the
amount of input sent to the cortex
from the thalamus which results in a
decrease in motor output from the
cortex.
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Etiology:
Though much is known about the structure and function of the BG and its role in
the development of PD, finding a single cause for the majority of idiopathic PD has
remained elusive. Current evidence indicates that both genetic and environmental
factors play an important role in the development of PD (for review see (Veldman et al.,
1998)). Genetic analysis utilizing twins has shown that for the majority of cases there is
not a significant effect of genetics on the development of PD (Duvoisin et al., 1981,
Marsden, 1987, Marttila et al., 1988), however, a rare mutation in the gene for αsynuclein has shown that an autosomal dominant form of PD does exist (Golbe et al.,
1990, Golbe et al., 1996, Polymeropoulos et al., 1996). With the likelihood of developing
PD solely because of a genetic mutation being low, the most likely causes for PD involve
an environmental component (Semchuk et al., 1993, Veldman et al., 1998). Exposure to
toxins such a paraquat (Liou et al., 1997), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) (Langston et al., 1983), or TCE (Gash et al., 2008) have been shown to be
linked to the development of PD in humans. Even with links between certain chemicals
and the development of PD, a study looking a environmental causes of PD could not
establish a link between the duration or level of exposure and disease development
(Hertzman et al., 1994). The difficulty in establishing a human link between the level of
chemical exposure and the development of PD is likely to be further complicated by the
belief that PD arises from a multifactorial process (Carvey et al., 2006). The premise of
a multifactorial model for PD is that a single insult is insufficient to drive disease
development and that the interaction of multiple insults results in a greater level of
pathology. Considering the potential necessity for more than one insult opens the
possibility that sub-pathological levels of single insults can interact and either additively
or synergistically lead to pathology.
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Traumatic brain injury is another factor which has been linked to the development
of PD and could interact in a multifactorial mechanism. Bower et al. showed that
individuals which experienced either a TBI which resulted in a loss of consciousness or a
severe TBI had an increased risk of developing PD later in life (Bower et al., 2003) and
TBI was shown in a separate study to be the second most likely cause of PD in humans
(Semchuk et al., 1993). TBI has been shown to produce alterations in the striatum which
are similar to PD (Donnemiller et al., 2000) and experimental studies have shown that
following a severe TBI there are deficits in the striatal DA system (Wagner et al., 2005).
The link between TBI and PD likely involves both direct and multifactorial mechanisms.
Human and experimental research indicates that, independently of other insults, TBI can
damage the BG and produce alterations similar to what has been observed in human PD
patients. If an individual who experiences a TBI is also exposed to an environmental
toxin it could be expected that the pathological outcome would be more severe.
A common factor between PD, TBI, and toxins linked to PD is the involvement of
mitochondrial dysfunction (Ramsay et al., 1986, Vyas et al., 1986, Schapira et al., 1990,
Sullivan et al., 1998b, Sullivan et al., 1999c, Sherer et al., 2003, Lifshitz et al., 2004,
Bender et al., 2006). The environmental pollutant TCE (Gash et al., 2008, Liu et al.,
2010), the pesticide rotenone (Sherer et al., 2003), and the toxin MPTP (Nakamura et
al., 2000) have all been shown to produce mitochondrial dysfunction in the brain and are
linked to the development of PD. Mitochondrial dysfunction has been further linked to the
development of PD since two treatments which act at the mitochondrial level, CoQ10
(Shults et al., 2002) and creatine (Matthews et al., 1999), have shown promise in
treating disease symptoms in preclinical studies. The mechanisms by which
mitochondrial toxins lead to PD involve impairment of mitochondrial bioenergetic function
through the inhibition of mitochondrial respiration. By blocking the function of the
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electron transport chain, inhibitors lead to reductions in ATP levels and increases in
damaging ROS, both of which can lead to cell death (Chen et al., 2007b). In addition to
toxin induced mitochondrial dysfunction, genetic mutations in several genes encoding
mitochondrial proteins have also been linked to the development of PD. Mutations in DJ1 (Bonifati et al., 2003), Pink1 (Valente et al., 2004), and Parkin (Kitada et al., 1998)
have all been linked to PD in human studies and the mechanisms of pathology involve
mitochondrial components (for review see (Cho et al., 2010).
The link between genetic mutations in mitochondrial proteins further supports the
role of a multifactorial mechanism since studies utilizing the toxin 6-hydroxydopamine
have shown a requirement for specific mitochondrial proteins in order to develop
pathology (Gomez-Lazaro et al., 2008). The evidence from human and experimental
studies strongly supports the notion that there are many factors which can play a role in
the development of PD. Few cases exist that show a clear single insult mechanism of
disease development and that alone supports the concept of multi-insult pathway for
developing PD. The interactions between genetics and environmental insults likely drive
the loss of the DA neurons in the substantia nigra and lead to the classical histological
and motor impairments of PD.
Trichloroethylene:
Trichloroethylene (TCE), C 2 HCl 3 , is a halogenated hydrocarbon that has been
widely used as a solvent in the United States for degreasing, dry cleaning, food
processing, paint production, and as an anesthetic (EOHS, Bakke et al., 2007). It is
estimated that as of 1997 over 400,000 workers were annually exposed to TCE in the
workplace (ATSDR, 1997). TCE has been detected at 861 National Priorities List
hazardous waste sites, with 213 of these sites having completed exposure pathways
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Figure 1.6: Trichloroethylene structure and environmental exposure

Trichloroethylene consists of a carbon-carbon double bond which is attached to three
chloride ions. As of 1997, 861 National Priorities List toxic sites were contaminated with
TCE and of these, 213 also had complete exposure pathways which resulted in the
contamination of ground water systems and the potential exposure of the communities
around the site. The number of toxic sites containing TCE can vary widely between
states, however, every state which had data available contained at least one location
contaminated by TCE. (n.d. = no data provided, figure edited from ATSDR, 1997)

allowing TCE to reach the population in proximity to the site (Figure 1.6) (ATSDR, 1997).
Acute exposure to TCE can lead to narcotic symptoms and chronic exposure can lead to
encephalopathy, polyneuropathy, trigeminal affection, and hearing loss (EOHS).
Following exposure to TCE, deficits including memory impairment, sensorimotor
neuropathy, facial muscle twitching, and decreased facial sensation have been shown to
persist for years (Feldman et al., 1985). Kilburn conducted an age matched study of
people exposed to TCE by inhalation and well water and found that exposed individuals
exhibited significant deficits in reaction time, balance, blink responses, cognitive
function, and motor speed as compared to regional referents (Kilburn, 2002). Similar to
the finds of Kilburn, Gash et al. observed that in factory workers chronically exposed to
TCE for many years that exposure was linked to the development movement
impairments (Gash et al., 2008). Strikingly, the findings by Gash showed a link between
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the level of exposure to TCE and the development of pathology since individuals which
were directly working with the TCE developed worse symptoms than individuals which
worked more distantly and therefore exposed to lower levels of TCE by inhalation (Gash
et al., 2008).
Given the link between mitochondrial dysfunction and PD (Schapira et al., 1989)
and the evidence that TCE exposure can lead to PD (Kilburn, 2002, Gash et al., 2008),
rodent experiments sought to further elucidate the connection between TCE and PD
(Gash et al., 2008, Liu et al., 2010). Rats which were exposed to TCE for six weeks
exhibited significant mitochondrial bioenergetic impairment, a loss of tyrosine
hydroxylase positive neurons in the SN, and changes in dopamine turnover kinetics in
the striatum (Gash et al., 2008). Further analysis of the effects of TCE on the brain
revealed that exposure led to increases in mitochondrial oxidative damage,
accumulation of α-synuclein both in the SN and the dorsal motor nucleus of the vagus,
and motor impairment (Liu et al., 2010). The results from the animal studies support
what has been observed in humans exposed to TCE since experimental exposure to
TCE resulted in symptoms of PD including motor impairment.
It was hypothesized by Bringmann that the downstream metabolite of TCE, 1trichloromethyl-1,2,3,4-tetrahyro-β-carboline (TaClo), may be the component of TCE
exposure responsible for the deficits. TaClo has been shown in in vitro models to
significantly inhibit Complex I of the mitochondrial respiratory chain (Janetzky et al.,
1995) and induce apoptosis through the release of mitochondrial Cytochrome C (Akundi
et al., 2004). With the availability of both experimental (Grote et al., 1995, Janetzky et
al., 1995, Akundi et al., 2004) and clinical reports (Guehl et al., 1999, Kochen et al.,
2003) of mitochondrial and dopaminergic toxicity following exposure to either TCE or its
metabolite TaClo, evidence has accumulated to implicate TCE (Kochen et al., 2003) and
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TaClo (Bringmann et al., 1995b, Riederer et al., 2002) as relevant neurotoxins in the
development of PD. It has been shown that exposure to an environmental factor long
before the onset of symptoms of PD correlates with the future development of pathology
(Veldman et al., 1998, Brown et al., 2005, Landrigan et al., 2005) and this may be the
result of either a slow continuous neuronal decline or a predisposition towards increased
susceptibility to future insults.

Multifactorial pathogenesis of Parkinson’s disease:
The search for a single causative factor responsible for the development of PD in
humans has been a major difficultly in understanding the pathogenesis of the disease.
Causative factors such as exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) (Langston et al., 1983) or familial genetic mutations in the gene encoding αsynuclein (Golbe et al., 1990, Golbe et al., 1996, Polymeropoulos et al., 1996) have
been shown to independently result in pathology, however, these factors are not likely to
be the cause for most cases of idiopathic sporadic PD. With the difficulty finding single
insults which can independently produce models PD that involve a progressive loss of
dopamine neurons, attention has been given to the concept of a multifactorial
mechanism (Veldman et al., 1998, Carvey et al., 2006). Age is considered to be a major
factor in the development of PD and after age 50 up to 6% of dopamine neurons in the
substantia nigra are lost (Gibb and Lees, 1991). Given that the normal loss of nigral cells
is thought to be insufficient to independently produce functional impairment (McGeer et
al., 1977, Kish et al., 1992), Carvey proposed the idea that the combination of age and a
second insult may be required to drive disease development (Carvey et al., 2006). Given
that age is linked with the development of PD but the normal loss of nigral neurons is
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less than typically needed for functional impairment, a combination of genetics,
environmental factors such as herbicides, pesticides, and head trauma may be needed
to interact over the course of an individual’s lifetime to lead to pathology (for review see
(Veldman et al., 1998)).
Multifactorial experiments have shown that neurons can be made more
susceptible to future insults following exposure to a toxin (Arundine et al., 2004, Ling et
al., 2004b). Numerous studies show that a variety of dual injuries can produce increased
pathology in animal models of PD (Thiruchelvam et al., 2000a, Thiruchelvam et al.,
2000b, Arundine et al., 2003, Arundine et al., 2004, Ling et al., 2006, Fei and Ethell,
2008) and these represent potential scenarios for how human PD develops. Exposure
the herbicide Paraquat has been linked to an increased risk of PD development (Liou et
al., 1997), however, other reports indicate there is not a direct link between Paraquat
and PD (Koller, 1986). Exposure to another insult in addition to Paraquat exposure may
be the necessary link which allows some studies to find a link to PD development while
other studies do not. Thiruchelvam et al. showed that exposure the pesticide Maneb in
addition to Paraquat exposure produced even greater deficits to the DA system in animal
models (Thiruchelvam et al., 2000a, Thiruchelvam et al., 2000b, Thiruchelvam et al.,
2002). Combining age with toxin exposure revealed that older animals are more
susceptible to exposure to either Paraquat or Maneb alone and that the combination of
age, Paraquat exposure, and Maneb exposure produced the greatest deficits to the
dopaminergic system (Thiruchelvam et al., 2003).
In addition to insults which individuals experience as adults, it is also thought that
childhood insults may play a role in the development of PD later in life (Martyn and
Osmond, 1995). Rural living has been linked to the development of PD (Rajput et al.,
1986, Rajput et al., 1987) and decreased numbers of nigral dopamine neurons
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(Thiessen et al., 1990) and this may represent early life exposure to environmental
factors which caused these differences. In addition to rural living, exposures in utero,
such as from maternal bacterial infections, may play a role in disease development. In
an experimental prenatal exposure model, it has been shown that prenatal exposure to
the bacteriotoxin lipopolysaccharide (LPS) results in a decrease in the number of DA
neurons at birth (Ling et al., 2002) and that when the prenatal exposure is combined with
postnatal toxin exposure the loss of DA neurons is even more pronounced (Ling et al.,
2004a, Ling et al., 2004b). Whether toxin exposure occurs during development or after
birth, there is clear evidence that the combination of exposure to multiple toxins can
result in greater deficits in the DA system.

Peroxisome proliferator activator receptors:
PPARs in normal cellular function:
The peroxisome proliferator-activated receptors (PPARs) are members of the
nuclear receptor superfamily and regulate gene expression using various liganddependent and independent molecular processes. Three isoforms of the PPARs exist:
PPARα, PPARγ, and PPARδ, and each isoform is the product of a separate gene
(Dreyer et al., 1992, Michalik and Wahli, 1999, Torra et al., 2001). While these isoforms
have similar protein sequence and structure, they differ in their ligand-binding domains
and have different ligand specificity, tissue distribution, and biological actions (Guan et
al., 2002). PPARs regulate the expression of their respective target genes through the
interaction with 9-cis retinoic acid receptors and the formation of heterodimers (Kliewer
et al., 1992). Defects in PPAR genes do not result in major changes to basal function,
however, these changes lead to alterations in the ability to activate the PPAR receptors.
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Fatty acids and prostaglandins serve as endogenous activators of the PPAR system
under normal conditions (Forman et al., 1997, Kliewer et al., 1997, Berger et al., 2005)
and exogenously fibric acids and thiazolidinediones (TZDs) have been utilized as
pharmaceutical ligands (Forman et al., 1995, Lehmann et al., 1995, Forman et al.,
1997). Under normal physiological conditions PPARα and PPARγ function to control lipid
and glucose metabolism respectively (Berger et al., 2005). The pathways interact in
various ways such as the ability of PPARγ to initiate the storage of lipids (Debril et al.,
2001) and PPARα to control lipid metabolism.
Under injury conditions PPAR activation has been shown to modulate
inflammatory responses. The most common method utilized by PPARs to regulate gene
expression is through transrepression (Moraes et al., 2006). PPARs have been shown to
significantly modulate inflammatory processes through the regulation of genes such as
nuclear factor-kappa B (NFκB), activator protein-1 (AP-1), signal transducer and
activator of transcription (STAT), and nuclear factor of activated T cells (NFAT) (Ricote
et al., 1998, Delerive et al., 2001, Park et al., 2003, Bernardo and Minghetti, 2006). The
regulation of these genes allows the PPAR system to affect macrophages, microglia,
dendritic cells, endothelial cells, B cells, and T cells (Clark, 2002, Daynes and Jones,
2002, Hunter, 2007)). Inflammation and oxidative stress have been shown to play an
important role in cell death after injury (Andersen, 2004) and given the ability for PPARs
to regulate proteins such as NFκB, it has been proposed that they will be effective in
various neurological disorders (Feinstein, 2003).
PPARs in CNS disorders:
The PPARγ agonists Pioglitazone and Rosiglitazone are both FDA approved
drugs for diabetes treatment (for review see (Sood et al., 2000) and have been utilized
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as therapeutics in animal models of CNS injury (Besson et al., 2005, Kiaei et al., 2005,
Schutz et al., 2005, Collino et al., 2006, Chen et al., 2007a, McTigue et al., 2007, Park et
al., 2007, Chen et al., 2008, Feng et al., 2008, Hyong et al., 2008, Sun et al., 2008, Yi et
al., 2008, Allahtavakoli et al., 2009). Rosiglitazone has been previously shown to have a
higher binding affinity for the PPARγ receptor (Young et al., 1998), however,
Pioglitazone has been shown to more readily cross the blood brain barrier (BBB) (Berger
and Moller, 2002) as well as partially activate the PPARα receptor (Sakamoto et al.,
2000). Currently evidence exists showing that activation of either the PPARα (Chen et
al., 2007a, Chen et al., 2008) or PPARγ (Yi et al., 2008) pathways are protective in
models of TBI. However, given Pioglitazone’s increased brain penetration and activation
of two separate PPAR pathways it may yield a greater therapeutic potential for the
treatment of TBI ( for review see (Kapadia et al., 2008).
Treatment with the PPARγ agonist Pioglitazone following lipopolysaccharide
(LPS) induced brain inflammation has shown the ability to prevent both mitochondrial
impairment and neuronal cell loss (Hunter et al., 2007). The therapeutic use of various
PPARs has shown benefit in multiple CNS injury models including spinal cord injury
(SCI) (McTigue et al., 2007, Park et al., 2007), TBI (Besson et al., 2005, Chen et al.,
2007a, Chen et al., 2008, Yi et al., 2008), and stroke (Collino et al., 2006, Allahtavakoli
et al., 2009). Of the three known PPAR isoforms, PPARα and PPARγ have been the
most well studied in CNS injury and have been shown to reduce lesion size both in SCI
(McTigue et al., 2007, Park et al., 2007) and TBI (Yi et al., 2008), reduce inflammation
(Besson et al., 2005, Chen et al., 2007a, Park et al., 2007, Hyong et al., 2008, Kapadia
et al., 2008), minimize oxidative damage (Chen et al., 2007a, Yi et al., 2008), spare
neurons (McTigue et al., 2007, Park et al., 2007), and preserve behavioral function
(Chen et al., 2007a, McTigue et al., 2007, Park et al., 2007, Chen et al., 2008). In
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addition to the anti-inflammatory properties of PPAR ligands, treatment with PPAR
agonists have also been shown to protect neuronal vasculature after an ischemic insult
(Inoue et al., 2003). The protective effects of PPARs on the vasculature after injury has
been shown to involve the prevention of increases in matrix-metalloproteinase-9 along
with increasing levels of the protective protein Hemeoxygenease-1 (Pereira et al., 2005).
Along with traumatic and acute injuries, PPAR ligands have shown effectiveness in
experimental models of PD (Breidert et al., 2002). Following administration of the toxin
MPTP, treatment with the PPARγ ligand Pioglitazone resulted in reductions in glial
activation and cell loss in the substantia nigra (Breidert et al., 2002) as a result of
increases in IκBα and reductions in NFκB (Dehmer et al., 2004). PPAR activation has
been shown to be protective in other neurological disorders such as Alzheimers disease
(Heneka et al., 2005) and multiple sclerosis (Feinstein et al., 2002, Lovett-Racke et al.,
2004) through similar mechanistic processes. It is most likely the neuroprotective effects
afforded by treatment with PPAR agonists involve a pleotropic process whereby
activation of the PPAR system affects multiple pathways.
Summary:
A common aspect of many of the toxins linked to the development of PD is that
they can inhibit mitochondrial bioenergetic function. The maintenance of mitochondrial
function is critical to preventing cell death since neuronal ATP stores can be depleted
within minutes and lead to the initiation of cell death pathways (Nilsson, 2001). A toxin
which is capable of inhibiting the mitochondrial respiratory chain such as MPTP
(Ramsay et al., 1986, Vyas et al., 1986), rotenone (Sherer et al., 2003), TCE (Gash et
al., 2008, Liu et al., 2010), or TaClo (Janetzky et al., 1995), could produce a chronic
decrease in ATP levels making neurons more susceptible to future insults since the cell
would already be in a compromised state from energy depletion. Similar to the toxin
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exposure models showing increased loss of dopamine neurons after exposure to two
different toxins, the combination of mitochondrial inhibition and a second insult have the
potential to interact and produce greater pathology.
Head trauma has also been linked to the development of PD (Semchuk et al.,
1993, Bower et al., 2003) however it has not been shown to be independently causative
for the development of PD (Factor et al., 1988). Though it remains yet to be proven, the
ability for trauma to drive PD may involve other factors or insults to be on going (Koller et
al., 1989). Currently there is no complete understanding of how idiopathic sporadic PD
develops in humans. A likely scenario is that multiple environmental and genetic factors
exist which can potentiate disease development but that under most conditions human
exposure to only one factor is not sufficient to independently cause PD and therefore a
multifactorial insult is more capable of producing PD.
With the ability of TCE to affect mitochondrial function (Gash et al., 2008), it is
possible that exposure prior to a TBI may lead to a worse outcome. Additionally, regional
differences in mitochondrial function and/or the susceptibility to mitochondrial inhibition
may affect to development of pathology following toxin exposure and how the interaction
between the toxin and TBI occurs. Given the role TBI may play in a dual injury process,
and the impact TBI has as an individual condition, finding effective therapeutic
interventions will likely help in ameliorating both of these issues.

Copyright © Andrew David Sauerbeck 2011

38

Chapter 2
Traumatic brain injury and trichloroethylene exposure interact and produce
functional, histological, and mitochondrial deficits.

Introduction:
One of the pivotal, common pathways shared between traumatic brain injury
(TBI), toxin induced neurodegeneration, and Parkinson’s disease (PD) is the disruption
of normal mitochondrial function (Ramsay et al., 1986, Vyas et al., 1986, Schapira et al.,
1990, Sullivan et al., 1998a, Sullivan et al., 1999c, Sherer et al., 2003, Lifshitz et al.,
2004, Bender et al., 2006). To date, research has shown that these three insults may be
able to interact at the mitochondrial level. Given the similar changes in mitochondrial
function observed with these pathologies, exposure to a mitochondrial toxin prior to a
TBI is hypothesized to produce a multifactorial injury with pathological changes greater
than either insult alone.
Exposure to an environmental factor long before the onset of symptoms of PD
has been shown to correlate with the future development of pathology (Veldman et al.,
1998, Brown et al., 2005, Landrigan et al., 2005) and this may be the result of either a
slow continuous neuronal decline or a predisposition towards increased susceptibility to
future insults such as TBI. One such factor environmental factor which has been linked
to PD is trichloroethylene (TCE), C 2 HCl 3 . TCE is a halogenated hydrocarbon carbon that
has been widely used as a solvent in the United States for degreasing, dry cleaning,
food processing, paint production, and as an anesthetic (EOHS, Bakke et al., 2007). It is
estimated that as of 1997 over 400,000 workers were annually exposed to TCE in the
workplace (ATSDR, 1997). TCE has been detected at 861 National Priorities List
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hazardous waste sites, with 213 of these sites having completed exposure pathways
allowing TCE to reach the population in proximity to the site (ATSDR, 1997). Exposure
to TCE has been shown to cause mitochondrial dysfunction (Gash et al., 2008) and a
loss of dopaminergic neurons in the substantia nigra (Liu et al., 2010). The downstream
metabolite of TCE, 1-trichloromethyl-1,2,3,4-tetrahyro-β-carboline (TaClo), has been
shown to inhibit Complex I of the mitochondrial respiratory chain (Janetzky et al., 1995)
and induce apoptosis through the release of mitochondrial Cytochrome C (Akundi et al.,
2004). With the availability of both experimental and clinical reports of mitochondrial and
dopaminergic toxicity following exposure to either TCE or its metabolite TaClo, evidence
has accumulated to implicate TCE (Kochen et al., 2003, Gash et al., 2008, Liu et al.,
2010) and TaClo (Bringmann et al., 1995b, Riederer et al., 2002) as relevant neurotoxins
in the development of PD.
The development of PD has been linked to TBI both in epidemiological studies
(Factor and Weiner, 1991, Stern, 1991, Semchuk et al., 1993, Taylor et al., 1999, Bower
et al., 2003) and in clinical evaluations (Nayernouri, 1985, Doder et al., 1999). Patients
sustaining a mild head trauma with a loss of consciousness or a severe head trauma
have a significant increase in the probability of developing PD later in life (Bower et al.,
2003). Although there have been multiple reports linking TBI to PD (Factor and Weiner,
1991, Stern, 1991, Semchuk et al., 1993, Bower et al., 2003), current evidence only
shows TBI to be a risk factor and has failed to show a causative link (Factor et al., 1988).
The disruption of mitochondrial function and the initiation of cell death mechanisms may
play a direct role linking TBI and PD. Mitochondrial dysfunction after TBI can result in
reductions in ATP levels (Sullivan et al., 1998a), increases in lipid peroxidation (Sullivan
et al., 1998a), release of Cytochrome C and activation of apoptotic pathways (Sullivan et
al., 2002), resulting in cell death. The role of the mitochondria is critical after TBI since it
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is capable of functioning as a regulator of cell death mechanisms and these changes
likely worsen an individual’s outcome from an additional insult.
Given the numerous factors linked to PD, including TCE and TBI, the concept
that the development of PD involves a multifactorial injury has emerged (Semchuk et al.,
1993). Multifactorial experiments have shown that neurons can be made more
susceptible to future insults following exposure to a toxin (Arundine et al., 2004, Ling et
al., 2004b). A toxin, such as TCE, which is capable of inhibiting the mitochondrial
respiratory chain (Gash et al., 2008), could make neurons more susceptible to future
insults. The chronic inhibition of Complex I by TCE and a resulting decline in energy
stores may be the link allowing TCE and TBI to interact. Based on previous studies
showing dual injuries can produce increased pathology (Thiruchelvam et al., 2000a,
Thiruchelvam et al., 2000b, Arundine et al., 2003, Arundine et al., 2004, Ling et al.,
2006, Fei and Ethell, 2008), we sought to test the hypothesis that TCE exposure and TBI
can interact to produce a greater level of disease pathology. This is the first report of
these two insults being studied together and provides further support that sporadic PD
may be the result of a multifactorial process.
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Methods:

All studies were approved by the University of Kentucky Institutional Animal Care
and Usage Committee and utilized male Fischer 344 rats 16 weeks old (Harlan
Laboratory). Animals were housed in groups of three per cage with food provided ad
libitum and 12-hour light/dark cycles. For the first set of studies there were six treatment
groups which consisted of animals which were exposed to trichloroethylene or vehicle
followed by either a sham, mild (1.0mm), or moderate (2.0mm) brain injury. For lesion
volume and mitochondrial studies the mild (1.0mm) group was not generated. A total of
156 animals were utilized for the completion of these studies.

Trichloroethylene treatment and controlled cortical impact brain injury:
Animals were orally gavaged 0.6ml of either the olive oil vehicle (Kroger Pure
Olive Oil) or 1000mg/kg trichloroethylene (Sigma Aldrich) daily for either 1 week or 2
weeks using a 100mm gavage needle (Fine Science Tools) with a 16 gauge tip sized to
prevent insertion of the needle into the trachea. The health of the animals was monitored
during the entire duration of the experiments to ensure no animals became morbidly
sick. Following treatment with trichloroethylene, animals received either a sham brain
injury or a controlled cortical impact brain injury using previously established methods
(Sullivan et al., 1998b, Sullivan et al., 1999c, Sullivan et al., 2000c). Animals were
anesthetized with 2% isofluorane and placed in a Kopf stereotaxic frame for positioning
under a pneumatic impactor (Precision Science Instruments). A 6 mm craniotomy was
performed, with a hand trephine, lateral to the central fissure on the left side of the skull
centered between lambda and bregma. Animals in injury groups received a unilateral
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injury directly to the surface of the brain. The injury parameters consisted of a 1.0mm
deep impact for mild injured animals and a 2.0 mm deep impact for moderate injured
animals at 3.5 meters/second for 500ms. Sham animals received a craniotomy but did
not receive an impact to the brain. Following the injury a piece of Surgicel
(Johnson&Johnson) sized to fit into the craniotomy was placed directly on the brain. The
skull cap was replaced and secured in place with dental acrylic. Once the acrylic was
allowed time to harden, the scalp incision was closed with surgical staples. Animals were
removed from isofluorane and placed in a clean cage and body temperature was
maintained at 37oC with the use of a heating pad. Five to six animals per group were
utilized throughout all of the experiments. Following the brain injuries, animals were
housed in their home cages until post-injury behavioral analysis was begun.

Behavioral analysis:
Rotarod testing: Nine days after the brain injury surgeries Rotarod testing was
begun for all treatment groups. Animals were trained on a Rotarod (Med Associates Inc.)
for three days at speeds of 8rpm, 12rpm, and then 16rpm. On the fourth day (12 days
post TBI) animals were tested on the Rotarod using an accelerating speed starting at
3rpm and holding at 30rpm. The time animals were able to stay on the Rotarod on the
fourth day was determined by a timer built into the Rotarod which was stopped when the
animal fell off the Rotarod and blocked an infrared light sensor. Animals were tested
twice on the fourth day and the times for each trial were averaged for each animal.
Cylinder testing: Thirty days after the brain injury, animals underwent cylinder
testing to access alterations in paw placement. Animals were placed in a clear plastic
cylinder with a diameter of 19cm which was mounted on a plexiglass surface with an
angled mirror underneath to allow video recording of the animals for 5min. Video
recordings were performed using a digital video camera, and the footage was analyzed
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using QuickTime software (Apple Computer Inc.) with playback set at ½ actual speed.
The number of contralateral and ipsilateral paw touches was quantified blinded to
treatment group. The percentage of contralateral forepaw usage was calculated using
the formula

.

Histological analysis:
Following the completion of the cylinder testing, animals were sacrificed for post
injury histological analysis. Animals were anesthetized with sodium pentobarbital (Abbot
Laboratories) and transcardially perfused with saline followed by 4% paraformaldehyde.
The brains were removed and placed in 4% paraformaldehyde and 30% sucrose in PBS
for 24hrs. After 24hrs the brains were transferred to a 30% sucrose PBS buffer without
paraformaldehyde. Coronal sections 30µm thick were cut with a freezing microtome
throughout the rostral caudal extent of the entire brain. Nissl staining was performed to
visualize the intact regions of the cortex for cortical tissue sparing analysis. Quantitative
assessment of cortical damage employed an unbiased protocol using the Cavalieri
method as previously described (Sullivan et al., 2000c, Sullivan et al., 2002). All slides
were assessed blindly with respect to treatment group. For immunohistochemistry,
sections containing regions of interest were incubated overnight at 4°C with a primary
antibody. Slices were stained for tyrosine hydroxylase using a primary monoclonal
antibody (Chemicom) followed by a biotinylated anti-mouse secondary antibody (Vector).
Following the secondary antibody treatment sections were treated with an Avidin Biotin
Peroxidase Complex, Vectastatin ABC Kit (Vector). The tissue was developed with a
diaminobenzidine tetrahydrochloride (DAB) solution with nickel intensification to allow
stable long term staining and visualization with a light microscope. Bioquant Image
Analysis software (Bioquant, Nashville, TN) was used to estimate total cell number in the
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region of interest using the optical fractionator method (Mouton, 2002). This method
represents an unbiased quantitative technique that is independent of size and shape or
any conformational changes of cells. Detailed procedures regarding stereological
counting are similar to our previously published studies (Liu et al., 2008). Coronal
sections containing the substantia nigra (interaural 2.7-4.2) (Paxinos and Watson, 1998)
were used to estimate the total number of tyrosine hydroxylase (TH) positive cells in the
SN. A set of 6 systematic sections were sampled in an independent-random manner
from a total of 36-39 sections containing the entire reference space. On each stained
section the area containing the SN was identified using conventional landmarks
(Paxinos, 2004). An unbiased grid was overlayed on each section and a random number
system embedded in the software used to identify areas of the grid for counting. On
each identified grid position an unbiased counting frame was used for the optical
dissector. The counting frame was 150 X 150μm centered on the grid intersection. The
height of each dissector was determined with a digital z-axis encoder (Boeckeler
Instruments, Tucson, AZ).

Cells were identified using a 40X objective with a high

numerical aperture. The total number of cells (N) was estimated using the formula N =
Q • 1/hsf • 1/asf • 1/ssf where Q is the total number of cells actually counted, hsf is the
height sampling fraction, asf is the area sampling fraction, and ssf is the section
sampling fraction. Image Pro software was used for the quantification of the area of the
striatum immunoreactive for TH in a blinded fashion. High resolution images throughout
the entire striatum stained for TH were taken using an Olympus AX80 microscope. Using
Image Pro, the perimeter of the striatum was outlined and the percentage area which
was immunoreactive for TH was calculated. The average amount of immunoreactivity for
a single animal was calculated separately for both the ipsilateral and contralateral sides
of the brain.
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Western blot analysis:
Quantification of dopamine transporter and receptor levels in the striatum was
performed using standardized western blot protocols. Animals were asphyxiated with
CO 2 and rapidly decapitated. The striatum was rapidly dissected, placed into plastic
tubes, and the tubes were placed into a bath of dry ice and ethanol to rapidly freeze the
tissue. Samples were frozen at -80oC until homogenized. At the time of homogenization
samples were placed into lysis buffer (0.1M NaCl, 0.01M Tris-Cl, 0.001 EDTA, 1ug/ml
aprotinin, 100ug/ml phenylmethylsulfonyl fluoride) and homogenized using low intensity
sonication for 30 seconds. Samples were centrifuged at 13,800xG for 30min at 4oC. The
protein concentrations were determined with all the samples on the same plate using the
BCA protein assay kit and measuring absorbance at 560nm with a Biotek Synergy HT
plate reader (Winooski, Vermont). Protein separation was performed using a 4%
stacking gel followed by a 10% separation gel. Gels were run for one hour at 150 volts
and 4oC with constant stirring. Following gel separation, proteins were transferred to
nitrocellulose utilizing a wet transfer setup at 100 volts for one hour. Following protein
transfer to the nitrocellulose, blots were washed three times with TBS and blocked with
5% milk in TBS for one hour at room temperature. After blocking, blots were washed
three times with TTBS at room temperature with constant agitation. Primary antibodies
towards the proteins of interest were prepared in 5% milk in TTBS. For quantification of
the dopamine transporter, 40ug of protein was loaded per well and the primary antibody
(Millipore) was applied at a concentration of 1:1500 and incubated overnight. For
quantification of the dopamine receptor, 60ug of protein was loaded to the gel and the
primary antibody (Santa Cruz) was applied at a concentration of 1:800 and incubated
overnight. Following incubation with the primary antibody, blots were washed with TTBS
and incubated with an infrared secondary antibody (Rockland) at a concentration of
1:5000. Band intensities were determined using a Licor Odyssey infrared imager. Levels
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of each protein were expressed as a ratio of the protein of interest compared to the
amount of actin for the same sample. Six animals per group were utilized for western
blot analysis.

Mitochondrial isolation and oxygen consumption analysis:
Mitochondria from the striatum and substantia nigra were isolated using
differential centrifugation, nitrogen disruption, and a Ficoll gradient. Animals were
asphyxiated with CO 2 and rapidly decapitated. Dissected tissue was removed and
immediately placed in ice-cold isolation buffer (215mM Mannitol, 75mM Sucrose, 0.1%
BSA, 1mM EGTA, and 20mM Hepes at pH 7.2). Due to the small size of the substantia
nigra, three animals were combined for each mitochondrial sample, resulting in an n=1
for these three animals. Samples were homogenized and centrifuged at 1300xG for 3
minutes. Following the first spin the supernatant was placed in a fresh tube and the
pellet was resuspended in isolation buffer and spun at 1300xG for 3min. The
supernatant from the first and second spins were collected in separate tubes and spun
at 13,000rcf for 10 minutes. The pellets from both tubes were combined, resuspended in
400ul isolation buffer and placed in a nitrogen bomb at 1,200psi for 10min. The pressure
in the nitrogen bomb was rapidly released and the sample was placed as the top layer
on a Ficoll separation column which consisted of a 10% Ficoll layer and a 7.5% Ficoll
layer. The Ficoll column with sample was centrifuged at 100,00xG for 30min at 4oC using
a Beckman SW 55Ti rotor and ultra-centrifuge. The final mitochondrial pellet was
resuspended in isolation buffer without EGTA to yield a final concentration of
approximately 10mg/ml, and stored immediately on ice. To normalize the results, the
protein concentrations were determined with all the samples on the same plate using the
BCA protein assay kit and measuring absorbance at 560nm with a Biotek Synergy HT
plate reader (Winooski, Vermont). Following two week exposure to TCE, mitochondrial
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oxygen consumption was measured using a Clark-type electrode (Hansatech
Instruments, Norfolk, England) in a continuously stirred, sealed chamber at 37°C as
previously described (Sullivan et al., 2003). Isolated mitochondrial protein (100µg) was
suspended in respiration buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM
HEPES, 2 mM MgCl, 2.5 mM KH2PO4 at pH 7.2) in a final chamber volume of 0.25 mL.
Mitochondrial bioenergetic analysis was measured by the sequential administration of
substrates: 5mM Pyruvate, 2.5mM Malate, 150nM ADP, 1uM Oligomycin, and 1uM
FCCP. Five to six animals per groups were utilized for all of the mitochondrial studies.

Seahorse protocol for isolated mitochondria:
Experiments utilizing 1 week exposure to TCE were performed with the Seahorse
Biosciences XF24 for analysis of mitochondrial oxygen consumption. The following
protocol was utilized for the analysis of bioenergetic function in purified mitochondria
using the Seahorse Biosciences XF24 Flux Analyzer. Pyruvate/Malate and ADP,
Oligomycin, FCCP, or Rotenone and Succinate were injected sequentially through ports
A, B, C, and D, respectively, in the Seahorse Flux Pak cartridges to yield final
concentrations of 5 mM (Pyruvate), 2.5 mM (Malate), 1mM (ADP), 1 μg/ml (Oligomycin),
1 μM (FCCP) and 100 nM (Rotenone), 10 mM (Succinate) respectively.
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The following sequence was utilized for analysis following 1 week exposure to TCE and
TBI:
Protocol for standard mitochondrial analysis
Step
Command
1
Calibrate probes
2
Mix 1 minute
3
Time delay 1 minute and 30seconds
4
Mix 25 Seconds
5
Measure 2 minutes
6
Mix 1 minute
7
inject Port A (Pyruvate/Malate/ADP)
8
Mix 25 Seconds
9
Measure 2 minutes
10
Mix 1 minute
11
inject Port B (Oligomycin)
12
Mix 25 Seconds
13
Measure 2 minutes
14
Mix 1 minute
15
inject Port C (FCCP)
16
Mix 25 Seconds
17
Measure 2 minutes
18
Mix 1 minute
19
inject Port D (Rotenone/Succinate)
20
Mix 25 Seconds
21
Measure 2 minutes

Statistical analysis:
All experimental groups contained 3-6 animals/group. All data were evaluated
with a two-way analysis of variance (2-way ANOVA) followed by a post-hoc Bonferroni
test with significance set at p<0.05.
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Results:

Motor impairment occurs following exposure to TCE and a moderate TBI

Motor impairment is the major functional pathology associated with Parkinson’s
disease. To investigate the potential of this multifactorial model to produce behavioral
impairment, two behavioral tests were utilized: the Rotarod and Cylinder Test. Animals
were tested on the Rotarod 12 days post TBI and it was found that following exposure to
TCE and a moderate CCI a significant reduction of approximately 50% (Figure 2.1A,
p<0.01) in the amount of time spent on the Rotarod was observed, indicating impairment
in motor coordination and balance. At 30 days post TBI animals were analyzed using a
cylinder test to determine longer-term deficits in forepaw usage. With the cylinder test a
significant reduction in the usage of the contralateral forepaw was observed in animals
that were exposed to TCE and a moderate CCI, which decreased to 34% (Figure 2.1B,
p<0.05) of control animals. With the decrease in forepaw usage only being present
following a dual exposure to both TCE and a moderate CCI there is again support for a
dual injury mechanism. Both behavioral tests indicate that the dual injury consisting of
TCE exposure and a moderate TBI is required for functional deficits to appear and that
any of the single insults tested are incapable of producing these functional deficits.
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Figure 2.1: Exposure to TCE and a moderate TBI synergistically interact resulting
in functional impairment:

Exposure to both TCE for 2 weeks and a moderate controlled cortical impact TBI result
in significant motor impairment. A) Twelve days after the TBI animals exhibited
significant motor impairment as exhibited by a reduced ability to stay on a rotating rod.
Animals exposed to TCE and a moderate TBI have approximately a 50% reduction in
the length time able to stay on the Rotarod. B) Thirty days after the TBI forepaw usage
was assessed using the cylinder test and contralateral forepaw usage decreased to
34%. Both behavioral tests show the necessity for both insults to be present before
functional impairment occurs.

#=p<0.01, *=p<0.05; n=6; 2-Way ANOVA with Bonferroni post-test; Mean±SE
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Exposure to TCE and a moderate TBI leads to a loss of tyrosine hydroxylase
positive neurons in the substantia nigra

The major histological feature of postmortem Parkinson’s disease diagnosis is
the loss of dopamine neurons in the substantia nigra (SN). Following exposure to either
TCE or TBI alone there was no significant loss of TH positive neurons in the SN,
however, following the dual injury with TCE and either a mild or moderate cortical
impact there was a 13-17% loss of TH positive neurons in (Figure 2.2A, P<0.05). The
presence of a significant loss of TH+ cells only following the dual injury indicates that
exposure to both TCE and TBI can lead to a synergistic loss of dopamine neurons in the
SN and produce the major histological symptom of PD even with injury levels which are
incapable of independently producing pathology. To determine if the loss of TH+ cells
was the result of cell death or a loss of the tyrosine hydroxylase protein, Nissl positive
cells were also counted. Nissl staining revealed no significant loss of cells indicating that
the loss of TH+ neurons was the result of a loss of tyrosine hydroxylase and not cell
death.
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Figure 2.2 Exposure to TCE and TBI interact and result in TH-positive neuron loss
in the substantia nigra:

Exposure to both TCE for 2 weeks and a mild or moderate controlled cortical impact TBI
resulted in significant decreases in the number of TH-positive neurons in the substantia
nigra at 30 days post TBI. A) The dual injury consisting of TCE exposure and a TBI brain
injury resulted in a 13-17% loss of dopamine neurons in the substantia nigra. B)
Quantification of Nissl cells in the substantia nigra did not reveal any measurable
amount of cell loss indicating the loss of TH-positive neurons is due to a loss of the TH
protein and not the loss of cells. C) Representative images of the substantia nigra
stained for TH.
*=p<0.05; n=6; 2-Way ANOVA with Bonferroni post-test; Mean±SE
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Exposure to TCE and TBI does not affect striatal tyrosine hydroxylase fiber
density or levels of the dopamine transporter and dopamine receptor:

Following the loss of dopamine neurons in the substantia nigra in human PD
there is a resulting loss of both TH+ fibers and the pre-synaptic dopamine transporter
(DAT) in the striatum along with an increase in the type-2 post-synaptic dopamine
receptor (D2R). Following either exposure to TCE, TBI, or both, no changes were
observed in the area of fibers positive for tyrosine hydroxylase in the striatum (Figure
2.3A). Additionally, there were no observable changes in the levels of DAT or D2R
following any of the single insults or the dual injury (Figure 2.3C,D).

Exposure to TCE does not affect cortical tissue loss following TBI
Following a controlled cortical impact (CCI) injury there is the formation of a
cortical cavity which results from the loss of neuronal tissue. Given the ability for TCE to
impair mitochondrial function, and the role mitochondrial dysfunction plays in post-TBI
cortical tissue loss, the amount of spared cortical tissue was measured in both single
and dual injured animals. Following a moderate CCI there is approximately a 30% loss
of tissue (Figure 2.4A, *=p<0.0001). Exposure to the mitochondrial toxin TCE prior to the
CCI did not lead to an increase in the size of the cortical lesion (Figure 2.4A). Unlike the
behavioral results, there was no additive effect in the cortex following exposure to both
TCE and TBI.
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Figure 2.3 Exposure to TCE, TBI, or the dual injury does not lead to striatal
changes in TH-fibers, DAT, and D2R.

Neither exposure to TCE for 2 week, a mild or moderate TBI, nor any combination of the
insults resulted in histological deficits in the striatum. A) The amount of area in the
striatum immunoreactive for TH was quantified and no reduction in TH-positive fibers
was measured. B) Representative images of the striatum stained for TH. C,D) Western
blot analysis for levels of the dopamine transporter and type-2 dopamine receptor
revealed no changes in either protein. n=6; 2-Way ANOVA; Mean±SE
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Figure 2.4: Exposure to TCE prior to a moderate TBI does not increase cortical
tissue loss.

Animals which were exposed to TCE for 2 weeks prior to a moderate TBI did not exhibit
an increase in the amount of cortical tissue loss. A) With this model and moderate TBI
resulted in approximately a 30% loss of cortical tissue at 30 days post-injury. Exposure
to TCE had no effect on the loss of cortical tissue. B) Representative images of Nissl
stained cortex 30 days post-injury.
*=p<0.0001; n=6; 2-Way ANOVA with Bonferroni post-test; Mean±SE

Two week TCE exposure impairs mitochondrial bioenergetic function in the
striatum
Mitochondrial dysfunction is a common feature of TBI, PD, and TCE exposure.
The ability for both TBI and TCE exposure to independently inhibit mitochondrial function
is hypothesized to be a potential mechanism allowing these insults to interact and
increase pathology. Mitochondria were isolated six hours after the CCI and total
mitochondria from both the striatum and substantia nigra were analyzed to determine
mitochondrial bioenergetic function. No reductions in mitochondrial function were
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observed in the substantia nigra six hours after the TBI or following the two week
exposure to TCE (Figure 2.5A). At six hours post injury exposure to TCE produced
significant mitochondrial impairment in the striatum which was observed by reductions in
both the basal and maximal rates of Complex I dependent oxygen consumption by
approximately 75% (Figure 2.5B, *=p<0.05). Exposure to the TBI alone resulted in a
non-significant trend towards reduced Complex I function in by approximately 30% in the
striatum. The combination of TCE exposure and a TBI did not result in a measureable
change mitochondrial function in the striatum when compared to TCE exposure alone.

Figure 2.5: Two week exposure to TCE results in decreased bioenergetics in the
striatum.

Animals were exposed to TCE for 2 weeks and then subjected to a moderate TBI and
mitochondrial tissue was isolated from the striatum and substantia nigra six hours postinjury. A) Analysis of mitochondrial bioenergetic function in the substantia nigra revealed
no significant difference between any of the treatment groups. B) Exposure to TCE for 2weeks produced significant reductions of approximately 75% in Complex I dependent
basal and maximal rates of mitochondrial oxygen consumption. TBI alone resulted in a
trend towards reduced mitochondrial function in the striatum, however, this decrease did
not reach significance.

*=p<0.05, n=5-6; 2-Way ANOVA with Bonferroni post-test; Mean±SE
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One week exposure to TCE followed by TBI results in synergistic mitochondrial
dysfunction in the striatum
Given the 75% reduction in Complex I driven mitochondrial function in the
striatum following 2 week exposure to TCE (Figure 2.5), and the difficultly this produces
in elucidating whether an interaction between TCE exposure and TBI exists, additional
animals were subsequently administered TCE for only 1 week. Following exposure to
TCE alone for 1 week there was not a reduction in Complex I driven mitochondrial
respiration. Similarly to the previous 2 week exposure studies, a moderate TBI resulted
in a non-significant decrease in mitochondrial bioenergetic function of approximately
30%. When the 1 week exposure to TCE was combined with a moderate TBI,
mitochondrial bioenergetic function was reduced by approximately 50% (Figure 2.6,
*=p<0.05). These studies indicate that TCE and TBI are capable of interacting at the
mitochondrial level which leads to significant mitochondrial dysfunction requiring the
presence of both insults.
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Figure 2.6: One week exposure to TCE followed by a moderate TBI results in
mitochondrial dysfunction in the striatum.

Exposure to either TCE for 1 week of a moderate TBI did not result in significant
mitochondrial dysfunction in the striatum. When the two separate insults were combined
together there was a significant reduction in the Complex I driven rate of mitochondrial
oxygen consumption. The dual injury paradigm resulted in significant mitochondrial
impairment which was measured as a 50% reduction in mitochondrial respiration.
*=p<0.05, n=3-4; 2-Way ANOVA with Bonferroni post-test; Mean±SE
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Discussion:
It has been proposed that in humans, the development of Parkinson’s disease
(PD) may involve a multifactorial mechanism (Semchuk et al., 1993). Genetic factors (for
review see (Nuytemans et al., 2010)), age (Naoi and Maruyama, 1999), and the toxin
MPTP (Langston et al., 1983, Langston and Ballard, 1983) have been shown to
independently lead to the development of PD in humans independently of other factors,
however, with the vast majority of other insults, such as TBI, or environmental exposures
it has been difficult to show causation for disease development (for review see (Veldman
et al., 1998)). Previous work from our group has shown that both in humans and rodents
chronic exposure to trichloroethylene (TCE) is capable of producing pathologic features
of PD such as motor impairment, loss on dopamine neurons in the substantia nigra and
striatal deficits in tyrosine hydroxylase (Gash et al., 2008, Liu et al., 2010). Even though
chronic high dose exposure is capable of leading to the development of Parkinsonism or
complete PD in both humans and animals (Gash et al., 2008, Liu et al., 2010), it is
unknown how many individuals would be exposed to high levels of TCE chronically. In
the present studies we investigated the potential for a lower exposure to TCE combined
with a traumatic brain injury (TBI) to produce a multifactorial model of PD. These studies
provide an initial indication that TCE and TBI can interact in a multifactorial mechanism.
It has been established using various combinations of insults and toxin
exposures that a multifactorial injury can produce a greater insult both in vitro (Arundine
et al., 2003, Arundine et al., 2004, Fei and Ethell, 2008) and in vivo (Thiruchelvam et al.,
2000a, Thiruchelvam et al., 2000b, Ling et al., 2006). In neuronal culture, cells which are
exposed to a mechanical stretch injury prior to NMDA exposure are made more
susceptible to the toxic insult (Arundine et al., 2003, Arundine et al., 2004). In rodents it
has been shown that prenatal toxin exposure can make animals more susceptible to
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future insults, resulting in a progressive model of PD (Ling et al., 2006), and that
multifactorial toxin exposure can produce a greater insult than exposure to a single insult
(Thiruchelvam et al., 2000a, Ling et al., 2006). Epidemiological studies have attempted
to find a potential link between TBI and PD (Bower et al., 2003). However, a causative
link between TBI and PD has been difficult to show and as a result it has been proposed
that the link between TBI and PD may involve a multifactorial mechanism (Semchuk et
al., 1993).
The major pathological symptoms of PD are progressive impairment in motor
control and loss of dopamine neurons in the substantia nigra. To investigate the potential
for a dual injury model to recapitulate the motor impairments and cell loss observed in
PD, both Rotarod and cylinder testing were utilized to assess motor function and
tyrosine hydroxylase (TH) staining was utilized to analyze both dopamine neurons in the
substantia nigra and dopamine fibers in the striatum. For our initial studies two different
severities for the TBI were utilized since it has been shown in human studies that the
severity of the injury significantly affects the link between TBI and PD (Bower et al.,
2003). Following a 2 week exposure to TCE and a moderate controlled cortical impact
(CCI) TBI, impairments were observed both with the Rotarod (Figure 2.1A) and cylinder
test (Figure 2.1B) indicating not only that the dual injury paradigm in these experiments
is required for motor impairment but also that a moderate and not a mild TBI is required
for the presentation of motor impairment. To determine whether a loss of dopamine
neurons in the substantia nigra was linked to the dual injury, TH-positive neurons were
quantified and it was observed that, in contrast to the behavioral data which indicated
that TCE exposure and a mild TBI did not result in dysfunction, exposure to TCE and
either a mild or a moderate TBI is sufficient to produce a loss of TH-positive neurons
(Figure 2.2A). Additionally, the loss of TH-positive cells was also shown to be the result
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of a loss of the TH protein and not cell loss, since quantification of Nissl cells did not
result in any group differences (Figure 2.2B). Though the behavioral analysis and THpositive cell counts did reach statistical significance in these studies, the deficits were
not as substantial as we hypothesized they would be. The results indicate that the
individual insults are insufficient to produce any impairment independently which is
desirable in this model since the major goal was to show a dual injury effect, however,
different injury parameters may have yielded us a more substantial dual injury model.
Specifically with regards to the TBI, had the injury been located directly over the striatum
or been more severe we may have been able to observe more profound alterations in
our endpoints.
Since a moderate TBI was required for motor impairment to occur, further
experiments were conducted utilizing this level of injury. Given the loss of TH-positive
neurons, the area of TH-positives fibers in the striatum was determined. As was
expected for only a 13-17% loss of cells in the substantia nigra, no measurable decrease
in TH-fiber density was observed in the striatum (Figure 2.3A). Since the levels of the
dopamine transporter have been shown to be reduced in a similar model of TBI which
utilizes a severe injury (Wagner et al., 2005), striatal tissue was analyzed both for levels
of the dopamine transporter (DAT) and the type-2 dopamine receptor (D2R). Following
either single insult or the dual injury, no reductions in the levels of DAT or D2R were
observed one month following the injury (Figure 2.3C,D). The lack of a reduction in the
DAT is likely the result of a more central and less severe TBI than previous reports
(Wagner et al., 2005). Further tissue analysis was conducted looking at cortical tissue
loss following the dual injury paradigm. A 30% loss of cortical tissue was observed
following the moderate TBI and exposure to TCE did not increase this loss (Figure 2.4A).
Since there was not an increase in cortical tissue loss, the data suggests that the main
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TCE effects are not in the cortex. The lack of observable changes in the levels of DAT
and D2R further indicate that at one month following the dual injury, this paradigm
produces a very mild dual injury model.
Mitochondrial dysfunction is a major pathological mechanism involved in TBI
(Sullivan et al., 1998a, Sullivan et al., 1999c, Singh et al., 2006) as well as a common
factor of many toxins linked to PD (Nakamura et al., 2000, Sherer et al., 2003, Gash et
al., 2008, Liu et al., 2010). It has been previously shown that either exposure to TCE
(Gash et al., 2008, Liu et al., 2010) or the metabolite TaClo (Bringmann et al., 1995a,
Janetzky et al., 1995) are capable of producing significant impairment in mitochondrial
bioenergetic function. In order to understand if exposure to TCE is capable of leading to
greater mitochondrial dysfunction following TBI, animals were exposed to TCE for two
weeks and then subjected to a moderate CCI injury. Tissue was isolated from both the
striatum and substantia nigra six hours after the brain injury since mitochondrial
dysfunction has been shown to peak early after TBI (Singh et al., 2006). Samples from
the substantia nigra revealed no significant impairments in mitochondrial function at six
hours after the injury (Figure 2.5A). In contrast to the lack of an effect in the substantia
nigra at six hours post-TBI, the striatum exhibited significant mitochondrial dysfunction.
In these studies a significant reduction in mitochondrial function was produced as a
result of exposure to TCE (Figure 2.5B), which made it difficult to observe a dual injury
effect since it appears that mitochondrial bioenergetic function has potentially reached a
maximal amount of impairment which cannot be increased. This bottoming out effect
likely occurs since any further decrease in bioenergetic function would most likely lead to
cell death and the mitochondria would no longer survive for analysis. Exposure to TCE
resulted in approximately a 75% reduction in both basal and maximal rates of Complex I
dependent mitochondrial bioenergetic function. A trend towards a reduction in
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mitochondrial function was observed in the striatum following exposure to TBI alone,
however, this effect did not reach significance. As predicted for the other endpoints, had
the TBI occurred directly over the striatum it is hypothesized that this decrease would
become more pronounced. Given the large reduction in mitochondrial function in the
striatum following the 2 week exposure to TCE and the difficulty this presents for
measuring increases in this deficit due to a subsequent TBI, further experimentation was
conducted using a 1 week exposure to TCE. Following exposure to TCE for 1 week
there was no decrease in Complex I driven mitochondrial function in the striatum. As
observed in the previous mitochondrial experiments, exposure to the TBI alone resulted
in a non-significant trend towards mitochondrial impairment of approximately 30%. When
the 1 week exposure to TCE was combined with the TBI, a significant reduction of
approximately 50% was observed in the striatum six hours after the injury (Figure 2.6).
The experiments utilizing the 1 week exposure of TCE show that the two insults are
capable of interacting at the mitochondrial level to produce a greater amount of
dysfunction than either insult alone is capable of.
The requirement for a multifactorial injury to produce the pathology shown in this
study is in line with what has been seen in humans, where many insults have been
determined to be risk factors for the development of human PD, but it has been difficult
to show whether these same risk factors are able to independently produce pathology.
This dual injury model utilizes toxin and injury levels which are individually insufficient to
produce motor impairment or a loss of TH-positive neurons, hallmarks of human PD.
However the dual injury produces significant reductions in both outcomes, indicating that
sub-acute exposure to multiple insults can interact to produce a significant injury and
lead to disease development. Previous studies have shown that insults targeting the
striatum can result in the progressive loss of TH-positive neurons in the substantia nigra
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(Sauer and Oertel, 1994) and that striatal mitochondrial inhibition results in DA
dysfunction (Zeevalk et al., 1997). Since both TCE exposure and TBI are capable of
producing reductions in striatal mitochondrial function, it is predicted that this
mitochondrial impairment leads to the reductions in TH-positive nigral neurons observed
in these studies in the same way as other models. What is striking about this study is
that motor impairment is present with levels of dopamine neuron loss which are lower
than typically seen from nigral neuron loss alone (Lee et al., 1996). The likely cause for
the motor impairment in this model is that in addition to the observed nigral deficits there
is striatal mitochondrial dysfunction which impairs normal synaptic function and a loss of
cortical tissue. The presence of neuronal death and dysfunction in multiple
interconnected regions of the brain likely leaves the system unable to overcome the
combinatorial insult. Given the lack of a significant decrease in tyrosine hydroxylase
positive fiber density in the striatum it would be unexpected that the typical therapeutic
utilized in humans, levodopa, would be capable of alleviating any of the motor
impairment. Since a percentage of human PD patients are non-responsive to levodopa,
this dual injury paradigm my recapitulate certain aspects of non-levodopa responsinve
PD.
Our initial study sought to utilize insults which would be insufficient to produce
pathology in our endpoints since we wanted to show a dual injury effect. However,
utilizing insults that do not independently produce pathology makes it difficult to know
what levels of the insults are ideal for this dual injury model. The results presented in
these studies do suggest that the dual injury hypothesis is valid; however, the lack of
overwhelming histological changes makes determining the role of these changes in PD
development difficult to prove. The lack of an effect on striatal protein expression at 30
days post-TBI suggests that the injury parameters utilized in the present study are not
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sufficient to elicit permanent changes in the striatum. Given the changes in striatal
proteins in human PD patients (Donnemiller et al., 2000) and that other animal models
recapitulate some of these changes (Wagner et al., 2005), future attempts to combine a
toxic insult with TBI should focus on injury parameters which directly target the striatum
and are thus more likely to elicit these changes. The mitochondrial results following the 1
week exposure to TCE do show that these two insults can interact at the mitochondrial
level to produce significant dysfunction.
These studies are the first to shown an in vivo dual injury model which utilizes
TBI, a major risk factor of PD, as a component of the injury paradigm. These studies
further implicate the mitochondria as a central component of TCE exposure, TBI, and
PD, especially in the striatum. Given the lack of increased cortical tissue loss when TCE
is administered prior to the TBI and previous evidence that more chronic exposure to
TCE can lead to deficits in the substantia nigra (Gash et al., 2008, Liu et al., 2010), it is
likely that the basal ganglia, especially the striatum, is more susceptible to TCE
exposure. Previous studies have shown that other mitochondrial toxins do appear to
predominately affect the basal ganglia (Koutouzis et al., 1994, Ferrante et al., 1997) and
that this effect is likely due to a these regions having lower levels of spare electron
transport chain capacity (Fern, 2003). These studies provide further support that TBI
can play a role in the development of PD and that a multifactorial injury paradigm can
produce greater pathology. Given the observed deficits in this study, future work
incorporating TBI in a dual injury PD model should attempt to more directly target the
basal ganglia in order to have a greater ability to elicit deficits. The present findings do
support the concept of a multifactorial mechanism for the development of PD and further
experimental refinement of this model will help in elucidating the complex interactions of
these insults across multiple brain regions.
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A short coming in this work, which could be addressed with further
experimentation, is the limited time points utilized for the various endpoints. The initial
goal of the project was to determine if TCE and TBI could interact and produce a dual
injury model of PD. Given that PD is a chronic condition which does not improve on its
own, acute time points were not utilized for the behavioral analysis. Previous work in
rodents has shown that following many experimental models of traumatic injury there is
a spontaneous recovery in behavioral function which occurs. Since the individual
behavioral tests were only conducted on single days, we are unable to determine in the
dysfunction is constant, improves with time, or gets worse with time. Future
experimentation with the model would be made stronger if behavioral analysis for the
individual tasks were performed over multiple days, both acute and chronic, for each
test. In addition to performing more time points for the behavioral analysis, the
quantification of dopamine neurons in the substantia nigra would be made stronger by
the addition of later time points. In the present experiments cell counts were performed
30 days post injury, only a loss of phenotypic dopamine neurons was observed. Given
the progressive nature of PD in humans, determining the number of dopamine neurons
in the substantia nigra at more time points would provide at least two benefits. First, it
could be further determined in the loss of phenotypic dopamine neurons continued or if
the cells went on to die or were able to recover and start producing dopamine again.
Secondly, by performing cell counting at later time points it could be concluded if cell
loss increases with time in a similar manner as observed in humans. By further
expanding the time points for the behavioral and histological analysis the ability to
determine if this model results in progressive degeneration, similar to what is observed
in humans, and to further understand the interaction of the two insults would be made
stronger.
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In addition to expanding the number of time points utilized in these studies,
incorporation of additional endpoints would increase the understanding of this model. In
human PD there is the development of α-synuclein inclusions and exposure to TCE in
rats has also been shown to result in the formation these inclusions. Given the link
between both TCE induced α-synuclein inclusion formation and the occurrence of these
inclusions in human PD, this endpoint would help both by providing and endpoint which
one of the factors in this model, TCE, is already known to affect and could be potentially
made worse by a second endpoint as well as providing further endpoints shown to be
affected in human PD. Additionally, markers of neuronal death such as silver-stain or
Flurojade staining could be utilized which would help to assess damage not only in the
cortex of basal ganglia as has already been performed but also in other regions of the
brain which as of yet have not been utilized for analysis. Furthermore, analysis of the
post-synaptic neurons could provide significant understanding about the current model.
The present experiments looked mainly at the pre-synaptic dopamine neurons which
project from the substantia nigra to the striatum. Recent unpublished data has shown
that following traumatic brain injury in rats there is a significant alteration of the
phosphorylation status of the post-synaptic protein DARPP-32 (bales poster). Given the
role this protein plays in the normal function of dopaminergic signaling in the basal
ganglia (for review see (Fisone et al., 2007) it would be expected that changes in the
proteins regulation would affect basal ganglia functioning. Given the previous evidence
of changes to this protein following TBI, and that many other post synaptic proteins may
have been altered in the present studies which result in deficits in motoring functioning,
detailed analysis of the post-synaptic neurons would help in determining if TBI, TCE, or
the interaction of the two affect the pre-synaptic and post-synaptic neurons differently.
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As mentioned previously, significant modification to the method of performing the
TBI would be expected to have a profound effect on the endpoints in the current model.
Previous experiments utilizing cortical impact to look at changes to the dopaminergic
system have positioned the injury directly over the striatum and utilized a more severe
impact and this injury paradigm results in more significant changes than were observed
in the experiments present here (Wagner et al., 2005, Wagner et al., 2009). Had we
utilized different injury parameters we expect that the observed effects of the TBI on the
striatum would be more severe. What should also be cautioned against though is
producing too severe of an injury which would prevent or hinder the ability to observe a
dual injury affect. As was observed with the 2 week TCE mitochondrial analysis, if the
mitochondrial dysfunction is too large it can be impossible to determine if the dual injury
resulted in more impairment. If the location of the TBI is altered in future experiments
some endpoints such as changes to proteins like the DAT or D2R could become
significant, however, other endpoints such as mitochondrial dysfunction may increase to
the point where a dual injury effect is not able to be observed. In addition to changing the
location of the TBI, changing the type of TBI could have a profound effect on the effect of
the dual injury and on the understanding of the developed of human PD and the role of
TBI in disease development. Recent unpublished work from the University of Kentucky
has indicated that moderate severity diffuse brain injury results in significant dysfunction
to the substantia nigra (Lifshitz poster). Following this injury paradigm there is a
significant increase in microglial activation and reactive astrogliosis along with a loss of
neurons in the substantia nigra. The cell loss associated with this TBI paradigm is
greater at month following the brain injury alone than was observed with the TCE TBI
paradigm present here. Future work looking at the interaction of TCE and TBI should
strongly consider model of TBI utilized in the experiments since damage to the
substantia nigra and potentially the rest of the basal ganglia could be must greater if a
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diffuse brain injury instead of a cortical impact based brain injury is combined with the
TCE exposure.
The current studies are limited by endpoints and time points utilized for the
determination of the insults both independently and together. Future work on this model
should seek to expand the endpoints utilized for histological analysis as well as expand
the number of time points utilized for motor function analysis. Changes to both of these
aspects of the current project would greatly improve the ability to determine the effect
the insults have and whether the model truly does represent of potential mechanism for
the development of PD in humans. Additionally, and potentially more siginificantly than
adding and expanding endpoints, careful planning should be performed to determine
what model(s) of TBI should be utilized for future studies. It could be of particular interest
to independtly test both changes to the parameters of the current model as well as
changing to a more diffuse injury paradigm since this would give the best ability to
determine not only if TBI plays a role in the development of human PD but also what
type(s) of TBI produce the most significant damage to the basal ganglia. These studies
provide an initial indication that TCE and TBI may be able to interact and produce more
pathology than either insult alone and future experiments should be able to help in
extending the findings of the current work.

Copyright © Andrew David Sauerbeck 2011
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Chapter 3
Regional mitochondrial function and toxin susceptibility

Introduction:
It is understood that regional differences play an important role in mitochondrial
function (for review see (Dubinsky, 2009)), however, there is limited evidence profiling
basal mitochondrial function or the susceptibility to mitochondrial inhibitors across
multiple brain regions. As shown in the previous chapter, the toxin trichloroethylene has
been shown to affect mitochondria in the striatum and substantia nigra differently,
however, there is no good understanding at this time why the two regions are
differentially affected. Many different factors have been shown to play a role the
observed regional differences in mitochondrial function such as enzyme activities
(Ryder, 1980, Gupta et al., 2000), requirements for oxidative phosphorylation (Hevner et
al., 1995), neuronal activity (Nie and Wong-Riley, 1996, Wong-Riley et al., 1997), and
spare respiratory capacity (Fern, 2003). Mitochondrial function has been shown to be
tightly linked with the cellular environment and events such as neurotransmitter induced
increases in intracellular calcium have been shown to directly affect the activity of
mitochondrial enzymes (Denton et al., 1988). Aside from rapid induction of changes in
mitochondrial function, regions which have high utilization of glucose have been shown
to contain more mitochondrial protein as determined by the level of Cytochrome Oxidase
(Humphrey and Hendrickson, 1983), indicating that long term changes in the regulation
of mitochondrial bionenergetics also exist. Additionally, the opposite effect has been
shown by reducing the activity of a particular brain region either by administration of the
sodium-channel blocker tetrodotoxin (Nie and Wong-Riley, 1996) or by blocking
peripheral sensory input (Tieman, 1985). These reductions in neuronal activity have
been shown to result in decreased amounts of mitochondria and mitochondrial proteins
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(Tieman, 1985, Nie and Wong-Riley, 1996). It is generally believed that one of the most
important factors controlling regional mitochondrial differences is higher levels of
neuronal activity which demand more ATP (Sokoloff et al., 1977). Even though regional
differences in oxygen consumption and mitochondrial numbers have been shown to be
linked to neuronal activity, this does not directly indicate that the individual mitochondria
are actually different. There are mitochondrial enzymes which do show regional
differences (Ryder, 1980, Gupta et al., 2000), however, this is not the case for every
enzyme. Many components of the TCA cycle have been shown to have similar activity
levels across brain regions suggesting that the mitochondria in different brain regions
may function similarly to each other (Marzatico et al., 1987, Curti et al., 1989, Dagani et
al., 1989, Villa and Gorini, 1991). A major difficulty in understanding whether regional
differences in mitochondrial function exist is that most studies typically utilize very few
brain regions, whole brain homogenates, or focus on synaptic versus non-synaptic
mitochondria. Factors such as the control of oxygen consumption by electron transport
chain components are similar in the cortex and hippocampus but differ significantly
between synaptic and non-synaptic mitochondria from the same brain region (Pathak
and Davey, 2008). The activity of Complex II of the mitochondrial electron transport
chain has also been shown to be similar between brain regions even though it differs
from non-neuronal tissue such as the heart and the liver (Mirandola et al., 2010).
Analysis of currently available experimental data suggests that the individual
mitochondria may function similarly across brain regions (Dubinsky, 2009) even though
some proteins have shown activity differences. Even though evidence suggests oxygen
consumption by isolated mitochondrial may be similar across brain regions, the
assumption has yet to be directly tested by looking at mitochondrial consumption of
oxygen across brain regions within a single study.
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Beyond

just

basal

mitochondrial

function,

another

aspect

of

regional

mitochondrial differences is the susceptibility of different brain regions to inhibition of the
mitochondrial electron transport chain (ETC). It has been established that toxins such as
3-nitropropionic acid or trichloroethylene produce regionally specific mitochondrial
dysfunction when given systemically (Beal et al., 1993, Gash et al., 2008) even though it
would be expected that more than just the affected brain regions are actually exposed to
the toxins. Mirandola et al. showed that there are regional differences in the activation of
the mitochondrial permeability transition by 3-NP even though inhibition of Complex II
enzyme activity is affected proportionally across brain regions (Mirandola et al., 2010). A
significant factor which likely plays a direct role in the regionally different susceptibilities
to mitochondrial inhibitors is the amount of spare respiratory capacity for a given
complex within a specific brain region (Fern, 2003). Interestingly, the regions with the
lowest spare respiratory capacities for a given mitochondrial complex appear to be the
ones most susceptible to inhibitors blocking that particular complex (Fern, 2003). The
current evidence on the effect of mitochondrial inhibitors across brain regions is difficult
to fully interpret since many of the studies only take limited factors into account. Davey
et al. showed that mitochondrial inhibitors which block different ETC complexes can
produce significantly different effects on oxygen consumption, however, the study
utilized whole brain mitochondria and so determining if regional differences exist is
impossible to determine (Davey et al., 1998). Mirandola et al. investigated the effect of 3NP on Complex II enzyme activity across brain regions, however, when investigating the
effect of 3-NP of oxygen consumption only a minimally dissected brain sample was
utilized (Mirandola et al., 2010). Studies investigating systemic toxin exposure of
mitochondrial toxins have shown regionally specific histological damage (Beal et al.,
1993, Liu et al., 2010) which suggests that mitochondrial function may be differentially
affected across brain regions. Since the amount of inhibition of enzyme activity is not
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always directly proportional to the amount of inhibition of oxygen consumption (Davey et
al., 1998), it is important to investigate both the inhibition of enzyme activity and oxygen
consumption in order to determine whether effects differ across brain regions. Given the
evidence which shows regionally specific damage following systemic toxin exposure, it
was hypothesized that regional differences in basal mitochondrial function or the
susceptibility of the mitochondria to Complex I or Complex II inhibitors may exist which
underlie the regionally specific histological damage.

Methods:
All studies were approved by the University of Kentucky Animal Care and Usage
Committee. Throughout all of the experiments, 16 week old male Fischer 344 rats
(Harlan) were utilized.

Mitochondrial isolation:
Total mitochondria were isolated using differential centrifugation, nitrogen
disruption, and a Ficoll gradient as previously reported. Animals were asphyxiated with
CO 2 and rapidly decapitated. Following decapitation, the brain was rapidly removed and
placed in a beaker of ice-cold isolation buffer (215mM Mannitol, 75mM Sucrose, 0.1%
BSA, 1mM EGTA, and 20mM Hepes at pH 7.2) to briefly cool. Anatomical regions of
interest were rapidly dissected apart and the tissue placed in ice-cold isolation buffer
until homogenization. Samples were homogenized and then centrifuged at 1300xG for 3
minutes at 4oC. Following the first spin the supernatant was placed in a fresh tube and
the pellet was resuspended in isolation buffer and spun at 1300xG for 3min at 4oC. The
supernatants from the first and second spins were collected in separate tubes and spun
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at 13,000xG for 10 minutes at 4oC. The pellets from both tubes were combined,
resuspended in 400ul isolation buffer and placed in a nitrogen bomb at 1,200psi for
10min. The pressure in the nitrogen bomb was rapidly released and the sample was
placed as the top layer on a Ficoll separation column which consisted of a 10% Ficoll
layer and a 7.5% Ficoll layer. The Ficoll column with sample was centrifuged at
100,00xG for 30min at 4oC using a Beckman SW 55Ti rotor and ultra-centrifuge. The
final mitochondrial pellet was resuspended in isolation buffer without EGTA to yield a
final concentration of approximately 10mg/ml, and stored immediately on ice. Protein
concentrations for each sample were determined with all the samples on the same plate
using the BCA protein assay kit and measuring absorbance at 560nm with a Biotek
Synergy HT plate reader (Winooski, Vermont).

Preparation of mitochondrial substrates and inhibitors:
Stocks of mitochondrial substrates were prepared as follows and stored at -20 oC
until further use. The concentrations for mitochondrial substrates were based upon
experience with the Clark-type oxygen electrode (Pandya et al., 2007, Pandya et al.,
2009) and optimized to obtain mitochondrial bioenergetic profiles which fit with
previously

observed

findings

obtained

with

the

oxygen

electrode.

500mM

Pyruvate/250mM Malate was prepared by combining 550 mg Pyruvate (Sigma P-2256),
335 mg Malate (Sigma M-7397), and 200 µl of 1M HEPES in 10 ml diH 2 0 and the pH
was adjusted to pH 7.2. A 30mM ADP stock was prepared by combining 128.2mg ADP
(Sigma A-5285) and 200 µl of 1M HEPES in 10 ml diH 2 0 and pH was adjusted to pH
7.2. A 1mg/ml Oligomycin-A stock was prepared by combining 1 mg Oligomycin-A
(Biomol CM-111) with 1ml methanol. A 1mM FCCP stock was prepared by combining
2.542 mg FCCP (Biomol CM-120) with 10 ml 100% ethanol. A 1M Succinate stock was
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prepared by combining 2.36g Succinic Acid (Sigma S-7501) with 400 µl of 1 M HEPES
in 20ml in diH 2 0 and the pH was adjusted to pH 7.2. Rotenone was prepared by first
combining 3.944mg rotenone (Biomol CM-117) with 10ml 100% ethanol for a final
concentration of 1mM. Rotenone was further serial diluted with 100% ethanol to obtain
final concentrations of 100uM, 10uM, 1uM, 100nM, and 10nM rotenone. Malonate stock
was prepared by first combining 1.04g Malonic Acid (Sigma M1296) with 10mL diH 2 0
and the pH was adjusted to 7.2 for a final concentration of 5M. KOH and HCl were
utilized for all pH adjustments.

Preparation and calibration of Seahorse sensor cartridge sample plate:

A Seahorse Bioscience XF24 extracellular flux analyzer was used to measure
mitochondrial function in intact isolated mitochondria. The XF24 creates a transient, 7 ul
chamber in specialized microplates that allows for the determination of oxygen and
proton concentrations in real time. The day before the planned experiment, 1ml of XF
Calibrant solution (Seahorse Bioscience) was added to each well of a 24 well dualanalyte sensor cartridge (Seahorse Bioscience). The sensor cartridge was placed back
on the 24 well calibration plate and put in a 37 oC incubator without CO 2 (Seahorse
Bioscience) overnight. The day of the experiment, the injection ports on the sensor
cartridge were loaded with the appropriate mitochondrial substrates or inhibitors at 10X
concentrations.

Once the sensor cartridge was loaded with all of the experimental

reagents it was placed into the Seahorse XF24 Flux Analyzer for automated calibration.
During the senor calibration, isolated mitochondria were then seeded in 50 ul volume of
respiration buffer containing 2.5 μg or 5 μg of protein (BCA method) per well in
polyethyleneimine-coated XF24 V7 cell culture microplates. Following the centrifugation
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of the plates at 2000rpm for 4 minutes at 4oC, 575ul of respiration buffer (215 mM
mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 2 mM MgCl, 2.5 mM KH2PO4 at
pH 7.2) at 37 oC was gently added to each well for a final volume of 625ul per well at the
beginning to the experiment. Plates were immediately placed into the calibrated
Seahorse XF24 flux analyzer for mitochondrial bioenergetic analysis.

Seahorse protocol for isolated mitochondria:
The following protocol was utilized for the analysis of bioenergetic function in
purified

mitochondria

using

the

Seahorse

Biosciences

XF24

Flux

Analyzer.

Pyruvate/Malate and ADP, Oligomycin, FCCP, or Rotenone and Succinate were injected
sequentially through ports A, B, C, and D, respectively, in the Seahorse Flux Pak
cartridges to yield final concentrations of 5 mM (Pyruvate), 2.5 mM (Malate), 1mM
(ADP), 1 μg/ml (Oligomycin), 1 μM (FCCP) and 100 nM (Rotenone), 10 mM (Succinate)
respectively.
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The following sequence was utilized for basal functional analysis:

Protocol for standard mitochondrial analysis
Step
Command
1
Calibrate probes
2
Mix 1 minute
3
Time delay 1 minute and 30seconds
4
Mix 25 Seconds
5
Measure 2 minutes
6
Mix 1 minute
7
inject Port A (Pyruvate/Malate/ADP)
8
Mix 25 Seconds
9
Measure 2 minutes
10
Mix 1 minute
11
inject Port B (Oligomycin)
12
Mix 25 Seconds
13
Measure 2 minutes
14
Mix 1 minute
15
inject Port C (FCCP)
16
Mix 25 Seconds
17
Measure 2 minutes
18
Mix 1 minute
19
inject Port D (Rotenone/Succinate)
20
Mix 25 Seconds
21
Measure 2 minutes

The same protocol was utilized for the log dose response experiments except
that rotenone or malonate were injected through Ports B, C, and D. For the time
dependent effect of rotenone administration a modified Seahorse mitochondrial protocol
was utilized for the repeated measure of oxygen consumption from the same well
following the injection of various low concentrations of rotenone (10fM, 10pM, 10nM).
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Analysis of data generated by Seahorse biosciences XF24:
For optimal analysis of mitochondrial bioenergetic function, the data generated
by the XF24 was further analyzed beyond the average oxygen consumption ratio
generated for a given measure. The methods for analyzing the Seahorse data are based
upon similar protocols for analyzing the rate of oxygen consumption using a Clark-type
oxygen electrode. During a given measure, the rate of oxygen consumption varies with
time as substrates bind with their targets or are consumed by the mitochondria. Using
the Excel software package (Microsoft), point-by-point rates are generated using the
AKOS algorithm written by Seahorse Bioscience. For Complex I and Complex II
function, the highest point-by-point rate is taken since as substrates are consumed the
rate begins to decrease. For the Oligomycin-A rate, an average of the last three pointby-point rates is taken since the effect of Oligomycin-A can take at least one minute to
reach maximal effect and an average of the last 30 seconds of the measure provides the
most consistent result.
Mitochondrial Complex I assay:
Mitochondrial Complex I enzyme activity was determined by measuring the
decrease in NADH absorption at 360nm in the presence and absence of rotenone, as
previously described (Gash 2008, Brown 2004). Frozen purified mitochondrial were
thawed and then diluted in 10mM KPO 4 pH 7.4 to a concentration of 1ug/ul. Samples
then underwent three cycles of five minute freezing on dry ice followed by five minutes of
thawing at 37oC followed by five seconds of sonication. The assay was performed in a
BioTek Synergy HT plate reader (BioTek, Winooski, VT) with excitation at 360nm and
emission at 460nm. 6ug of mitochondrial protein was added to 25mM KPO 4 pH 7.2,
5mM MgCl 2 , 1mM KCN, 1mg/ml bovine serum albumin, and 150uM NADH in a total
volume of 69ul. Either 1ul of 1mM rotenone or 1ul of 25mM KPO 4 pH 7.2 was added so
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that with and without rotenone samples could be compared. The reaction was started by
the addition of 30ul of coenzyme Q1 (final concentration 50uM). Enzyme activity was
calculated by subtracting the change in NADH emission in the absence of rotenone from
the change in NADH emission in the presence of rotenone.

Mitochondrial Complex II assay:
Mitochondrial Complex II enzyme activity was determined by measuring the
change in absorbance of DCIP at 600nm using a BioTek Synergy HT plate reader
(BioTek, Winooski, VT). Frozen purified mitochondrial were thawed and then diluted in
10mM KPO 4 pH 7.4 to a concentration of 1ug/ul. Samples then underwent three cycles
of five minute freezing on dry ice followed by five minutes of thawing at 37oC followed by
five seconds of sonication. 3ug of mitochondrial was added to 200mM KPO 4 pH 7.0,
20mM K-Succinate, 10uM EDTA, 0.01% Triton X-100, 0.5ug/50ul coenzyme Q10, ~20%
DCIP for a total volume of 50ul. The starting optical density was between 0.6-0.8 at
600nm and the exact concentration of DCIP was made so that this starting density was
obtained. The change in absorbance was measured at the beginning of the experiment
and two minutes later. Enzyme activity was determined by subtracting the final optical
density from the initial optical density.
Statistical analysis:
For all experiments significance, was set at p<0.05. Analysis of the mitochondrial
protein dependent rate of Complex I oxygen consumption was performed with a twotailed t-test. Comparisons of basal mitochondrial function were conducted using a oneway analysis of variance followed by post-hoc analysis to determine group differences.
The log dose response experiments and the time dependent rotenone inhibitory effect
were analyzed using a two-way analysis of variance followed by post-hoc analysis to
determine group differences.
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Results:
Basal mitochondrial bioenergetic function across brain regions:
Mitochondria isolated from different regions of the brain exhibit differences in
mitochondrial bioenergetic function with the cerebellum and the striatum exhibiting
significant differences. Compared with the striatum, the cerebellum exhibited a 36%
slower rate of ADP dependent Complex I driven respiration. Additionally, analysis of
maximal Complex II driven respiration revealed that the striatum was approximately 1.6
times faster than the cerebellum. Both the striatum and the hippocampus exhibited
higher rates of residual oxygen consumption in the presence of the Complex V inhibitor
Oligomycin-A compared to the cerebellum. The respiratory control ratio (RCR) was
calculated to determine the overall health and integrity of the mitochondria and no
significant differences were observed between any of the brain regions. Additionally, the
RCR determinations revealed that the mitochondria utilized in these experiments were
all healthy since the RCRs were greater than 5.
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Figure 3.1: Regional differences exist in brain mitochondrial function.

Mitochondrial bioenergetic analysis reveals regionally specific variations in mitochondrial
function. A) Compared with the striatum, the cerebellum exhibited a 36% slower rate of
Complex I driven mitochondrial oxygen consumption. B) Similar to the Complex I
findings, analysis of Complex II dependent oxygen consumption revealed that the
cerebellum had a significantly slower rate of oxygen consumption. C) The striatum and
the hippocampus exhibited nearly two-fold higher rates of oxygen consumption in the
presence of Oligomycin-A. D) No significant differences exist between brain regions with
respect to the mitochondrial respiratory control ratio.
n=6/group. *=p<0.05 with One-way ANOVA and SNK-post test; #=p<0.05 with One-way
ANOVA and protected Fischer’s LSD
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Effect of mitochondrial Complex I and II inhibitors on enzyme activity:
Measurement of enzymatic activity was performed in order to determine the
direct action of the inhibitors on their respective mitochondrial targets. Analysis of the
effect on the Complex I specific inhibitor rotenone revealed that the concentration of
rotenone required to inhibit 50% of enzyme activity, the IC50, ranged from 163-238pM
and that no significant difference in the IC50 existed across brain regions (Figure 3.2).
Further analysis of the effect of rotenone revealed that Complex I enzyme activity was
equally affected across brain regions as the concentration of the inhibitor was increased.
Similar to the effects of rotenone, exposure to the Complex II inhibitor malonate resulted
in no significant differences in the calculated IC50 with values ranging from 440-580µM
across brain regions (Figure 3.2). As the concentration of the inhibitor was increased,
the resulting decline in Complex II enzyme activity was equal across all brain regions
tested.
Effect of mitochondrial Complex I and II inhibitors on oxygen consumption:
Mitochondrial enzyme activity does not always change proportionally to
mitochondrial oxygen consumption following treatment with a mitochondrial enzyme
inhibitor. Direct measurement of enzymatic activity was performed following inhibitor
administration to determine the effect of the inhibitors on their respective target
enzymes. Baseline values for the two inhibitors were calculated from mitochondrial
samples in the absence of inhibitor. Acute exposure to rotenone resulted in an
immediate dose dependent reduction in mitochondrial Complex I driven oxygen
consumption. Significant differences were observed across brain regions as a result of
exposure to rotenone. Following exposure to 10pM rotenone the cerebellum and
hippocampus were significantly more inhibited than the striatum or the cortex (Figure
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3.3, *=p<0.05). The hippocampus remained more inhibited than the striatum following
exposure to 100pM rotenone. All differences between brain regions went away at
concentrations of rotenone 1nM and higher. Exposure to malonate resulted in a dose
dependent decrease in mitochondrial driven oxygen consumption with no observed
differences across brain regions.
Figure 3.2. Mitochondrial Complex I and II inhibitors affect enzyme activity equally
across brain regions.

A) No differences were observed in the response of the different brain regions to
Complex I enzyme inhibition. As the amount of rotenone was increased, all of the tested
brain regions had similar percentage reductions in enzyme activity. B) The response to
Complex II inhibition was not significantly different across brain regions. Similar to the
effects observed following rotenone administration, as the concentration of malonate
was increased the various brain regions had similar decreases in enzyme activity. C) No
significant differences were observed in the calculated IC50 values across brain regions
and the reduction in enzyme activity in the presence of rotenone was comparable across
all brain regions tested. The calculated IC50 values for malonate did not differ
significantly between the brain regions tested.
n=3-5/group. Two-way ANOVA
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Figure 3.3: Regional differences exist in the susceptibility to rotenone but not
malonate.

A) At low concentrations of the mitochondrial Complex I inhibitor rotenone the
cerebellum and hippocampus are more susceptible to inhibition of oxygen consumption
than the striatum or the cortex. As the concentration of rotenone increased, the
differences between brain regions eventually went away. B) Exposure to the Complex II
inhibitor malonate produced dose dependent reductions in mitochondrial oxygen
consumption which did not differ across brain regions for a given concentration of
inhibitor.
n=5/group. *=p<0.05 Two-way Anova with Bonferroni post-test

Time dependent inhibition of Complex I by rotenone:
Human exposure to a toxin can occur over time frames longer than in vitro experiments
which typically assess inhibitory values are conducted. Isolated cortical mitochondria
treated with 10nM of the Complex I inhibitor rotenone exhibited a significant reduction in
mitochondrial oxygen consumption immediately following exposure. Lower doses of
rotenone, 10pM and 10fM, did not result in any reduction in oxygen consumption up to
eight minutes following exposure. If exposure to rotenone at 10pM was allowed to
continue a significant reduction in mitochondrial oxygen consumption became apparent
as early as 12 minutes following exposure (Figure 3.4, *=p<0.05). The decrease in
oxygen consumption following 10pM rotenone exposure eventually reached a 75%
reduction in mitochondrial oxygen consumption.

85

Figure 3.4: Exposure to 10pM rotenone produces a progressive decrease in
mitochondrial oxygen consumption.

Samples which were exposed to 10nM rotenone produced an immediate reduction in
oxygen consumption similar to previous finding. Similarly, exposure to 10fM rotenone
resulted in no reduction in oxygen. In contrast to acute measurements rotenone
dependent reductions in Complex I driven oxygen consumption, exposure to 10pM
resulted in a progressive reduction in mitochondrial oxygen consumption. For at least
eight minutes following exposure to 10pM rotenone no reduction in oxygen consumption
was observed. As early as 12 minutes following exposure to 10pM rotenone a significant
reduction in oxygen consumption occurred that continued to decrease with time. A 75%
reduction in Complex I driven oxygen consumption was observed at 16 minutes postexposure and this level of inhibition continued beyond this time point without further
reduction.
n=5/group. *=p<0.05 Two-way ANOVA with Bonferroni post-test
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Discussion:
Regional differences have been observed in the activity of specific mitochondrial
enzymes (Ryder, 1980, Gupta et al., 2000). Neuronal activity has been shown to play a
direct role in the expression of mitochondrial proteins (Wong-Riley et al., 1997) and
reductions in synaptic activity can lead to reduced Cytochrome-C levels (Nie and WongRiley, 1996) and the number of mitochondria (Tieman 1985). Additionally, ischemic
injury experiments have shown regionally different mitochondrial susceptibility to the
injury (Sims, 1991) which could be the result of mitochondrial or cellular environment
differences. Multiple groups have further, established that, in addition to brain region
differences in mitochondrial function there is a significant difference between synaptic
and non-synaptic mitochondria (Davey et al., 1997, Brown et al., 2006, Naga et al.,
2007, Pathak and Davey, 2008). Numerous factors are likely to play role in the
differential susceptibility of mitochondria such as which region of the brain the
mitochondria are from (Singh et al., 2010) or the cell containing the mitochondria
(Zeevalk et al., 1997).
In order to further elucidate the role of the mitochondria in regionally specific
toxin susceptibility, analysis of basal mitochondrial function was performed across
various regions of the brain. We hypothesized that regions which appear more
susceptible to Complex I or Complex II inhibition in vivo may have reduced basal
mitochondrial function. At the initial onset of these experiments we attempted to utilize
TaClo, a metabolite of TCE which has been shown to produce robust inhibition of
mitochondrial Complex I driven oxygen consumption (Janetzky et al., 1995). Though we
were able to obtain a sample of TaClo, problems with the solubility of the compound and
a limited amount of it precluded its use to the present studies. Given that TaClo is known
to inhibit mitochondrial Complex I, the much more usable inhibitor rotenone was utilized
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in these experiments for technical reasons. The results indicate that the greatest
differences in Complex I and Complex II dependent oxygen consumption exist between
the cerebellum and the striatum (Figure 3.1). The finding of reduced basal oxygen
consumption in the cerebellum compared to other brain regions has not been shown
before and therefore the underlying reason for this effect is currently unknown. Previous
work has show a reduced activity of Complex II enzyme activity in the cerebellum
(Fagundes et al., 2007) and this could be an underlying reason for the reduced Complex
II dependent oxygen consumption observed in these studies. It has recently been shown
that resting aerobic glycolysis is lower in the cerebellum than other brain regions
(Vaishnavi et al., 2010) and this may be the result of different ratios of neuronal and nonneuronal cells in the cerebellum (Azevedo et al., 2009). Interactions between neurons
and astrocytes during in vivo oxygen consumption has been shown to occur (Kasischke
et al., 2004) with the two cell types providing different roles during energy metabolism
(for review see (Magistretti, 2006). Given the higher percentage of neurons to astrocytes
in the cerebellum, the regional differences in the mitochondrial respiration observed in
the present studies may be affected by different cell type ratios. Basal Complex I and
Complex II dependent mitochondrial oxygen consumption did not differ between the
cortex, striatum, or hippocampus in these experiments which indicates that mitochondria
from these regions have similar bioenergetic capacities and profiles. Interestingly, the
cerebellum had a significantly slower rate of oxygen consumption in the presence of the
Complex V inhibitor Oligomycin-A compared to the striatum and hippocampus (Figure
3.1B). The difference in oxygen consumption in the presence of Oligomycin-A may be
the result of lower levels of glutathione and superoxide dismutase in the striatum and
hippocampus relative the cerebellum (Sanchez-Iglesias et al., 2009) which could
possibly allow for increased damage to the inner mitochondrial membrane and increased
proton leak across the damaged membrane. Calculation of the mitochondrial Respiratory
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Control Ratio revealed high levels of coupling between the pumping of protons across
the inner membrane with the formation of ATP by Complex V (Figure 3.1D).
Differences in mitochondrial spare respiratory capacity have been documented
which may provide insight into the regional heterogeneity of in vivo mitochondrial toxin
models. Previous reports utilizing the toxin trichloroethylene (Gash et al., 2008, Liu et al.,
2010) or 3-Nitroproionic acid (2-NP) (Beal et al., 1993) have shown that different regions
of the brain do appear more susceptible than other regions. Mirandola showed that
following in vitro systemic exposure to the mitochondrial Complex II inhibitor 3-NP there
are regional differences in the susceptibility to mitochondrial permeability transition in
mitochondria isolated from the brain. However, in isolated mitochondria in vitro treatment
with 3-NP affected mitochondria equally across the same brain regions (Mirandola et al.,
2010). It has been suggested that one of the major reasons certain brain regions are
more susceptible than other to a particular toxin is not the mitochondria itself but the
environment the cells are in (Mirandola et al., 2010). Analysis of the susceptibility of
isolated mitochondria to Complex I or Complex II inhibition indicates that there are no
differences between brain regions with regards to the effect these toxins have on
enzyme activity (Figure 3.2). This finding is in agreement with results looking at Complex
II activity and the susceptibility to 3-NP where the cortex, striatum, and cerebellum had
similar basal enzyme activities and susceptibilities to inhibition (Mirandola et al., 2010). It
has previously been shown that the percentage inhibition of mitochondrial Complex I
activity is correlated with the percentage reduction in mitochondrial oxygen consumption
(Davey et al., 1998). The current results support this previous finding since the dose
dependent reduction in mitochondrial oxygen consumption in the presence of the
Complex I inhibitor rotenone (Figure 3.3A) is similar to of the reduction in Complex I
enzyme activity (Figure 3.2A). The present study further extends this effect to Complex II
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dependent oxygen consumption since the effect of the inhibitor malonate had a similar
concentration dependent effect on oxygen consumption (Figure 3.2B) as it did on
enzyme activity (Figure 3.3B). These results further indicate that at low concentrations of
the inhibitor rotenone differences in the percentage reduction of oxygen consumption
does differ between brain regions (Figure 3.3A).
Previous unpublished experiments from our group indicated that a time
dependent effect of rotenone on Complex I dependent mitochondrial function may exist
at low concentrations of the inhibitor. To test if this effect was real, repetitive
measurements were taken of mitochondrial samples treated with either 0, 10fM, 10pM,
or 10nM rotenone. As shown in our previous experiments (Figure 3.4), the 10nM
rotenone produced an immediate significant reduction in oxygen consumption while the
10pM rotenone did not produce an immediate reduction in oxygen consumption (Figure
3.4). Strikingly, continued exposure to the 10pM rotenone produced a clear time
dependent reduction in Complex I dependent oxygen consumption which became
significant by 12 minutes post injection and reach a 75% reduction in oxygen
consumption by 16 minutes (Figure 3.4). This is an important finding to consider when
attempting to determine the IC50 for a compound or comparing results from multiple
groups which utilize different methodologies.
These results show that there are no significant differences in basal
mitochondrial bioenergetic function in samples isolated from the cortex, striatum, or
hippocampus. The cerebellum did exhibit significant differences in basal mitochondrial
function but the susceptibility to mitochondrial Complex I and Complex II inhibitors
remained proportional to the other brain regions. Like the cerebellum, the other regions
of the brain were relatively similar to mitochondrial enzyme inhibition except at low
concentrations of rotenone where regional differences did become apparent. The effect
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of rotenone on Complex I function is further shown to be significantly time dependent at
a 10pM concentration.
A major factor which must also be considered when interpreting these results is
that the studies are carried out with equal amounts of purified mitochondria. These
studies provide insight into the function of isolated mitochondria from different brain
regions but do not give evidence for the amount of in vivo mitochondrial oxygen
consumption across these regions. Previous reports have established that reductions in
neuronal activity can lead to reduced numbers of mitochondria (Tieman, 1985) or
amounts of mitochondrial proteins (Nie and Wong-Riley, 1996), which would impact the
amount of oxygen consumption per volume of tissue and factors such as these are not
addressed with these studies. Future experimentation should utilize techniques such as
immunohistochemical or western blot analysis for the amount of mitochondrial proteins
or the quantification of the number of mitochondria in order to determine regional
differences in the amount mitochondria across brain regions. Furthermore,

positron

emission tomography has been utilized to assess the consumption of pyruvate within the
brain in vivo (Toyoda et al., 1989) and further investigation utilizing this technique or
measurement of brain glucose utilization would help to further the understanding of
regional mitochondrial differences. Utilizing in vivo techniques for the measurement of
mitochondrial function would also allow for the determination of the effect of the various
mitochondrial toxins directly on the intact brain regions. An additional level of in vivo
differences which these studies do not address is the role of metabolic coupling between
neurons and astrocytes. Evidence has accumulated which indicates coupling of energy
processing machinery between these two cell populations in such a way that their
metabolic processes function as a single unit (Kasischke et al., 2004) (for review see
(Magistretti, 2006)). Considering that the mitochondria in the current experiments are no
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longer inside individual cells, it is conceivable that the mitochondrial pathways may
function differently in vitro compared with in vivo. By using techniques which do not
disturb the brain regions, cells, or mitochondria it is possible that the results of these
experiments could be significantly different than what is present presently. The major
findings from these studies are that the mitochondrial machinery function similarly across
brain regions, with the exception of the cerebellum. Additionally, mitochondrial Complex I
and Complex II inhibitors equally affect different regions of the brain except for lower
concentrations of rotenone. These studies further suggest that the observed regionally
specific histological changes which occur following systemic exposure to a mitochondrial
inhibitor (Beal et al., 1993, Liu et al., 2010) are not likely to be the result of regional
differences in the individual mitochondria.

Copyright © Andrew David Sauerbeck 2011
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Chapter 4
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical
tissue loss, and inflammation following traumatic brain injury.

Introduction:
Traumatic brain injury (TBI) pathology results from both a primary injury and a
secondary injury cascade. The primary injury is due to biomechanical damage which
results in the shearing and compression of neuronal, glial, and vascular tissue. The
cascade of secondary injury damage, which occurs in the hours and days following the
initial insult, is due to activation of pathophysiological cascades, consisting of complex
biochemical and cellular pathways that influence progression of the injury, such as
alterations in excitatory amino acids (Yamamoto et al., 1999, Rose et al., 2002),
increased reactive oxygen species (ROS) production (Marklund et al., 2001, Hall et al.,
2004, Tavazzi et al., 2005), disruption of calcium homeostasis (Mattson and Scheff,
1994, Xiong et al., 1997, Sullivan et al., 1999c), post-traumatic neuroinflammation
(Morganti-Kossmann et al., 2001, Vlodavsky et al., 2006) and mitochondrial dysfunction
(Azbill et al., 1997, Xiong et al., 1997, Sullivan et al., 1998b, Sullivan et al., 1999a,
Sullivan et al., 1999b). As a result of these secondary injury processes, there are
significant reductions in ATP levels (Sullivan et al., 1998a), increases in lipid
peroxidation (Sullivan et al., 1998a), release of cytochrome c (Sullivan et al., 2002) and
activation of apoptotic pathways (Sullivan et al., 2002), all of which can lead to the
initiation of cell death pathways. Mitochondria are a major component of this secondary
injury pathway because they function as a highly sensitive gatekeeper of cell death
mechanisms and as the primary energy producer for the cell. As such, mitochondria play
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a pivotal role in cerebral energy metabolism, intracellular calcium homeostasis, and ROS
generation and detoxification.
Following TBI, a significant disruption of mitochondrial homeostasis has been
documented that results in a decline in cellular bioenergetics, increased mitochondrial
ROS production and a decline in synaptic equilibrium (Azbill et al., 1997, Xiong et al.,
1997, Sullivan et al., 1998b, Sullivan et al., 1999a, Sullivan et al., 1999b). Therefore,
following TBI, the degree of mitochondrial injury or dysfunction can be an important
determinant of cell survival or death (for reviews see (Robertson, 2004, Sullivan et al.,
2005, Robertson et al., 2006) and therapeutic treatments designed to protect and
stabilize the mitochondria have demonstrated the ability to reduce injury in preclinical
studies (Sullivan et al., 2000a, Pandya et al., 2007). Although preclinical research has
identified neuroprotective agents which target mitochondrial function, inflammation, and
oxidative damage, attempts to move therapies into clinical usage have so far been
unsuccessful (Schouten, 2007). Given the complexity of the secondary injury, it has
been suggested that drugs which target multiple pathological pathways may yield more
effective therapeutic approaches for TBI. The PPARγ agonist Pioglitazone has been
shown to reduce inflammation (Besson et al., 2005, Chen et al., 2007a, Park et al.,
2007, Hyong et al., 2008, Kapadia et al., 2008) and oxidative damage (Chen et al.,
2007a, Yi et al., 2008), attenuate mitochondrial dysfunction (Hunter et al., 2007), and
reduce cell death (McTigue et al., 2007, Park et al., 2007) following CNS injury.
Pioglitazone’s ability to target multiple injury mechanisms may provide it with an
advantage over other therapeutics for TBI which target a single secondary injury
cascade. Treatment with Pioglitazone following LPS induced brain inflammation has
shown the ability to prevent both mitochondrial impairment and neuronal cell loss
(Hunter et al., 2007). The use of various PPARs has shown benefit in multiple CNS
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injury models including spinal cord injury (SCI) (McTigue et al., 2007, Park et al., 2007),
traumatic brain injury (TBI) (Besson et al., 2005, Chen et al., 2007a, Chen et al., 2008,
Yi et al., 2008), and stroke (Collino et al., 2006, Allahtavakoli et al., 2009). Of the three
known PPAR isoforms, PPARα and PPARγ have been the most well studied in CNS
injury and have been shown to reduce lesion size both in SCI (McTigue et al., 2007,
Park et al., 2007) and TBI (Yi et al., 2008), reduce inflammation (Besson et al., 2005,
Chen et al., 2007a, Park et al., 2007, Hyong et al., 2008, Kapadia et al., 2008) , minimize
oxidative damage (Chen et al., 2007a, Yi et al., 2008), spare neurons (McTigue et al.,
2007, Park et al., 2007), and preserve behavioral function (Chen et al., 2007a, McTigue
et al., 2007, Park et al., 2007, Chen et al., 2008).
The PPARγ agonist Pioglitazone is an FDA approved drug for diabetes treatment
(for review see (Sood et al., 2000)) and has been utilized as a therapeutic in multiple
animal models of CNS injury (Besson et al., 2005, Kiaei et al., 2005, Schutz et al., 2005,
Collino et al., 2006, Chen et al., 2007a, McTigue et al., 2007, Park et al., 2007, Chen et
al., 2008, Feng et al., 2008, Hyong et al., 2008, Sun et al., 2008, Yi et al., 2008,
Allahtavakoli et al., 2009). Pioglitazone has been shown to more readily cross the blood
brain barrier (BBB) than the similar drug Rosiglitazone (Berger and Moller, 2002) as well
as partially activate the PPARα receptor (Sakamoto et al., 2000). Pioglitazone’s
increased brain penetration and activation of two separate PPAR pathways may yield a
greater therapeutic potential for the treatment of TBI (for review see (Kapadia et al.,
2008)). Currently, evidence exists showing that activation of either the PPARα (Chen et
al., 2007a, Chen et al., 2008) or PPARγ (Yi et al., 2008) pathways are protective in
models of TBI, however, no studies currently exist showing the effect of Pioglitazone
following TBI. Because of the success of PPAR agonists in multiple models of CNS
injury and their offer of a broad range of potentially protective properties, it is
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hypothesized that PPAR activation by Pioglitazone will be beneficial in an animal model
of controlled cortical impact (CCI) that has hallmarks of human TBI. The current project
addresses the hypothesis that Pioglitazone will offer significant neuroprotection leading
to maintenance of mitochondrial function, sparing of cortical tissue, attenuation of
inflammation, and preservation of cognitive function following TBI.

Methods:
All studies were approved by the University of Kentucky Institutional Animal Care
and Usage Committee. Male Sprague Dawley rats weighing 250 grams (Harlan
Laboratory, IN) were utilized throughout all experiments.
Controlled cortical impact brain injury:
Animals were anesthetized with 2% isofluorane and placed in a Kopf stereotaxic
frame for positioning under a pneumatic impactor (Precision Science Instruments). A 6
mm craniotomy was performed, with a hand trephine, lateral to the central fissure on the
left side of the skull centered between lambda and bregma. Animals in injury groups
received a unilateral injury directly to the surface of the brain. The injury parameters
consisted of a 1.5mm deep contusion at 3.5 meters/second for 500ms. Sham animals
received a craniotomy but did not receive an impact to the brain. Following the injury a
piece of Surgicel (Johnson&Johnson) sized to fit into the craniotomy was placed directly
on the brain. The skull cap was replaced and secured in place with dental acrylic. Once
the acrylic was allowed time to harden, the scalp incision was closed with surgical
staples. Animals were removed from isofluorane and placed in a clean cage and
temperature was maintained at 37oC with the use of a heating pad.
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Pioglitazone treatment:
Following the completion of the brain injuries, animals were randomly assigned to
drug treatment groups. Pioglitazone and the antagonist T0070907 were prepared by
adding 1mg of the compound to 25uL of 100% Ethanol, 1uL 38% HCl, and 25uL of 0.9%
saline. This mixture was vortexed briefly and then 200uL of 0.9% saline was added.
Each day, the drugs were made fresh for each set of injections. Pioglitazone or the
PPARγ antagonist T0070907 were administered at 10mg/kg/injection. The vehicle
administration group was administered the same solution used to dissolve the
Pioglitazone and the antagonist. All injections were administered intraperitoneally. For
mitochondrial analysis experiments treatments were started 15 minutes following the
injury and depending upon the group a second injection was administered 24 hours
later. For the behavioral and histological experiments treatment was begun 15 minutes
after the injury and continued with subsequent injections at 24h, 48h, 72h and 96h after
the first injection.
Morris water maze behavioral assessment:
Morris water maze testing was begun 10 days post-surgery and consisted of four
trials per day for five consecutive days. The maze consisted of a dark black circular pool
(170 cm diameter, 56 cm high) filled with water (27°C) to a depth of 30 cm. A clear
circular Plexiglas platform 13 cm in diameter was placed 2 cm below the surface and
served as the goal platform. A video camera placed directly above the center of the pool
recorded swimming performance. Each video record was processed by a video motion
analyzer (Videomex V; Columbus Instruments, Columbus, OH). The swim speed was
measured for each animal to ensure that observed changes were not secondary to
impairments in motor function. For each animal, goal latency and distance traversed to
the platform were measured for each of the four daily trials and averaged.
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Histological analysis:
After the completion of the behavioral testing, animals were sacrificed for
histological analysis. Animals were anesthetized with sodium pentobarbital (Abbot
Laboratories) and transcardially perfused with saline followed by 4% paraformaldehyde.
The brain were removed and placed in 4% paraformaldehyde and 30% sucrose in PBS
for 24hrs. After 24hrs the brains were transferred to a 30% sucrose PBS buffer without
paraformaldehyde. Coronal sections 35µm thick were cut with a freezing microtome
throughout the rostral caudal extent of the damaged cortex. Sections were stained with
neutral red and subjected to image analysis for lesion volume assessment. Quantitative
assessment of cortical damage employed an unbiased stereological protocol using the
Cavalieri method as previously described (Sullivan et al., 2000c, Sullivan et al., 2002).
All

slides

were

assessed

blindly

with

respect

to

treatment

group.

For

immunohistochemistry, sections containing regions of interest were incubated overnight
at 4°C with a primary antibody. The primary antibody for OX-42 (monoclonal, 1:2000,
PharMingen, San Diego, CA) was used to detect microglia. After washes and incubation
with an appropriate secondary antibody (Vector Laboratories, Burlingame, CA),
immunoreactive cells were visualized by the avidin-biotin immunoperoxidase method
(ABC

kits,

Vector

Laboratories)

tetrahydrochloride (Sigma).

with

chromogen

3,3’-diaminobenzidine

For each animal, sections at an interval of 770µm

throughout the injured cortex were utilized for microglia. Five sections were selected for
each animal and five non-overlapping adjacent fields of each section were selected
which surrounded the edge of the cortical lesion. A Nikon Eclipse 80i light microscope
with an attached Nikon microscope camera was used to obtain data images using a
200X objective. The images were captured and imported into Simple PCI image
processing software (Compix Inc.) for activated microglia counting.
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Mitochondrial isolation and bioenergetic analysis:
Cortical mitochondria were isolated using differential centrifugation, nitrogen
disruption, and a Ficoll gradient. Animals were asphyxiated with CO 2 and rapidly
decapitated. A cortical punch encompassing the injury site was removed and
immediately placed in ice-cold isolation buffer (215mM Mannitol, 75mM Sucrose, 0.1%
BSA, 1mM EGTA, and 20mM HEPES at pH 7.2). Samples were homogenized and
centrifuged at 1300xG for 3 minutes. Following the first spin the supernatant was placed
in a fresh tube and the pellet was resuspended in isolation buffer and spun at 1300xG
for 3min. The supernatant from the first and second spins were collected in separate
tubes and spun at 13,000xG for 10 minutes. The pellets from both tubes was combined,
resuspended in 400ul isolation buffer and placed in a nitrogen bomb at 1,200psi for
10min. The pressure in the nitrogen bomb was rapidly released and the sample was
placed as the top layer on a Ficoll separation column which consisted of a 10% Ficoll
layer and a 7.5% Ficoll layer. The Ficoll column with sample was centrifuged at
100,000xG for 30min at 4oC using a Beckman SW 55Ti rotor and ultra-centrifuge. The
final mitochondrial pellet was resuspended in isolation buffer without EGTA to yield a
final concentration of approximately 10mg/ml, and stored immediately on ice. To
normalize the results, the protein concentrations were determined with all the samples
on the same plate using the BCA protein assay kit and measuring absorbance at 560nm
with a Biotek Synergy HT plate reader (Winooski, Vermont). Mitochondrial oxygen
consumption was measured using a Clark-type electrode (Hansatech Instruments,
Norfolk, England) in a continuously stirred, sealed chamber at 37°C as previously
described (Sullivan et al., 2003). Isolated mitochondrial protein (100µg) was suspended
in respiration buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 2
mM MgCl, 2.5 mM KH 2 PO 4 at pH 7.2) in a final chamber volume of 0.25 mL.
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Mitochondrial bioenergetic analysis was measured by the sequential administration of
substrates: 5mM Pyruvate, 2.5mM Malate, 150nM ADP, 1uM Oligomycin, and 1uM
FCCP.
Statistical analysis:
All experiments were analyzed with a one-way ANOVA with post-hoc statistical
analysis to determine group differences. Significance for all experiments was set at
p<0.05.
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Results:
Pioglitazone
dysfunction.

protects

mitochondria

from

injury-induced

mitochondrial

Following TBI there is significant damage to the mitochondria resulting in
impaired bioenergetic function. In order to elucidate the effect of Pioglitazone on
mitochondrial bioenergetic function, two different treatment paradigms for Pioglitazone
administration were utilized. In the first set of animals, Pioglitazone was administered
15min after the injury (10mg/kg) and animals were sacrificed 25hrs after the injury. In the
second set of animals Pioglitazone was administered at 15min and 24hrs after injury
(10mg/kg/injection) and animals were sacrificed at 25hrs after the injury. Following injury
in both sets of animals, reductions in Pyruvate/Malate (PM), ADP, and FCCP
(uncoupled) respiration rates were seen in vehicle treated animals (Figure 4.1,
*=p<0.01). With only a single 15min injection there was a slight but non-significant
increase in respiration rates following Pioglitazone treatment (Figure 4.1A); however,
when Pioglitazone was given at both 15min and 24hrs after the injury a significant
increase in mitochondrial function was observed (*=p<0.01, Figure 4.1B), indicating that
under

these

conditions

Pioglitazone

treatment

mitochondria’s ability to produce ATP.
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leads

to

preservation

of

the

Figure 4.1. Pioglitazone treatment attenuates mitochondrial dysfunction after
traumatic brain injury.

In order to assess the ability of Pioglitazone to prevent the mitochondrial dysfunction
which occurs with this model of TBI, mitochondrial bioenergetic function was analyzed 1
day following a controlled cortical impact TBI. A. Following a single injection of
Pioglitazone (10mg/kg) 15 minutes after the injury, no improvements in mitochondrial
function were observed. B. When Pioglitazone was administered at both at 15 minutes
and 24 hours after the injury (10mg/kg/injection) a significant increase in mitochondrial
bioenergetics was observed. These studies indicate that treatment with Pioglitazone at
15 minutes and 24 hours is capable of preventing mitochondrial dysfunction following
TBI.
(* p<0.01 by one-way ANOVA with SNK post-test).
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Pioglitazone treatment improves Morris water maze performance following
traumatic brain injury.
Cognitive impairment is a significant pathological outcome with both human and
rodent cortical impact TBI. In order to assess the ability of Pioglitazone to reduce
cognitive impairment following injury, animals were administered vehicle, Pioglitazone,
or Pioglitazone plus the PPARγ antagonist T0070907 with an initial injection at 15 min
post-injury and subsequent injections at 24h, 48h, 72h and 96h after the first injection.
Pioglitazone and T0070907 were administered at 10 mg/kg at every dose. Morris water
maze (MWM) assessments were performed 10 days post-injury and consisted of 4 days
of trials. Following repeated measures analysis of the MWM results, a significant effect
of day (p<0.0001) and a trend towards effect of treatment (latency p=0.0693; distance
p=0.0648) were observed. To further elucidate the effect of Pioglitazone on MWM
behavior and increase statistical power, groups were collapsed across days. When
averaged across all testing days, the latency and distance to the platform showed
significant effects. Injured vehicle-treated animals showed impairments in both distance
(Figure 4.2A, *=p<0.05) and latency (Figure 4.2B, *=p<0.05) to the platform and
treatment with Pioglitazone significantly improved behavior. Treatment with the PPARγ
antagonist T0070907 and Pioglitazone together prevented the beneficial effects of
Pioglitazone following injury (Figure 4.2 p<0.05 Sham vs. Pio+Ant) since animals given
the antagonist with Pioglitazone performed similarly to injured vehicle-treated animals,
indicating direct involvement of the PPARγ receptor. No significant differences in swim
speed were observed among the treatment groups, suggesting that the differences in
MWM performance were not related to motor deficits.
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Figure 4.2. Pioglitazone treatment reduces cognitive impairment following
traumatic brain injury.

With this model of TBI there are impairments in Morris Water Maze (MWM) performance
following the injury. Pioglitazone was administered for 5 days following the injury in order
to determine if treatment with Pioglitazone is capable of preventing cognitive impairment
with the MWM test. Treatment with Pioglitazone produced a significant reduction in both
the distance and latency to find the platform following TBI. Additionally, animals which
were also treated with the PPARγ antagonist T0070907 exhibited no preservation of
function indicating that PPARγ receptor activation is required for Pioglitazone’s ability to
preserve cognitive functioning.
(* p<0.05 by one-way ANOVA).
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Pioglitazone treatment reduces cortical damage following traumatic brain injury.
Quantification of the cortical lesion was utilized to assess the efficacy of
Pioglitazone to reduce the cortical tissue loss which occurs following CCI brain injury.
Administration of Pioglitazone and the antagonist T0070907 was conducted in the same
manner as for the behavioral analysis, with injections of 10mg/kg beginning 15 minutes
after the injury and continuing at 24h, 48h, 72h and 96h after the first injection. A
moderate CCI injury (1.5 mm) resulted in a significant loss of cortical tissue (Figure 4.3).
At 16 days post-injury, the cortical contusion volume in the vehicle-treated control group
was measured to be 5.09±0.73mm3 (Figure 4.3B). Treatment with Pioglitazone resulted
in reduction of the lesion size by 55% to 2.27±0.27mm3 which was significantly smaller
compared to the vehicle treated TBI group (Figure 4.3B, *=p<0.05). Co-treatment of
Pioglitazone with the PPARγ antagonist T0070907 abolished the effect seen with
Pioglitazone treatment alone. Animals that were treated with Pioglitazone and the
antagonist had an average lesion size of 4.32±0.60 mm3 which was larger than the
lesion size in the Pioglitazone group (Figure 4.3B, *=p<0.05 Pio vs. Pio+Ant), suggesting
that the PPARγ receptor activation is involved in Pioglitazone’s ability to spare cortical
tissue. Administration of the PPARγ antagonist alone following the injury did not affect
the size of the cortical lesion.
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Figure 4.3. Pioglitazone treatment reduces cortical tissue loss.

Following a cortical impact brain injury there is significant loss of cortical tissue which
occurs in the days and weeks following the injury. Pioglitazone was administered for 5
days following a unilateral cortical contusion in order to access the ability of Pioglitazone
to reduce cortical damage. In these studies Pioglitazone treatment reduced the size of
the lesion which occurs in this CCI rat model of TBI. These studies also indicate that
activation of the PPARγ receptor is required for this aspect of Pioglitazone’s
neuroprotective function since treatment with the PPARγ antagonist blocked the
therapeutic effect. A. Representative coronal sections stained with neutral red for
animals treated with vehicle, Pioglitazone, or T0070907 and Pioglitazone at 16 days
post-injury. B. Lesion volume quantification showed a significantly reduced lesion
volume in Pioglitazone-treated CCI animals when compared with the vehicle group and
antagonist treatment prevented the effect (*=p<0.05, one-way ANOVA with SNK posttest).
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Pioglitazone attenuates the neuroinflammatory response after traumatic brain
injury.

Following TBI there is a significant increase in microglial activation and
inflammation and Pioglitazone was administered in attempts to reduce post-injury
inflammation. At 16 days after TBI, Pioglitazone-treated rats showed significantly fewer
OX-42 positive cells in the injured cortex adjacent to the injury site, suggesting a
reduction in both microglial activation and macrophage infiltration. The effect of
Pioglitazone on inhibiting the inflammatory process was assessed by stereological
quantification of the activated microglia. OX-42 immunoreactive cells exhibited two
morphologies: resting microglia with small cell body and multiple thin processes and
activated microglia with enlarged amoeboid cell body and pyknic processes. Following
injury there was a significant increase in the number of activated microglia (p<0.05
Figure 4.4B). In the injured cortex, the total number of activated microglia was reduced
in the Pioglitazone-treated group compared vehicle treatment (Figure 4.4B). Compared
with animals which received a sham injury, animals treated with Pioglitazone did not
show a significant increase in the number OX-42 positive cells. Treatment with the
PPARγ antagonist T0070907 did not prevent the effect of Pioglitazone on preventing the
increase in inflammation, indicating that the effect was not dependent upon the PPARγ
receptor.
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Figure 4.4. Pioglitazone reduces post-injury microglial activation following
traumatic brain injury.

With this cortical contusion model of TBI there is significant inflammation which occurs
following the injury. Pioglitazone was administered for 5 days following the injury in order
to assess its ability to reduce inflammation following TBI. In this model, Pioglitazone
attenuated the neuroinflammatory response in the injured animals. These studies also
show that Pioglitazone does not require the PPARγ receptor in order to reduce
inflammation following injury since treatment with the PPARγ inhibitor T0070907 did not
block Pioglitazone’s neuroprotective effects. A. Immunohistochemistry for OX-42 was
shown in cerebral cortex adjacent to the cortical lesion. The bottom images are high
magnification views of the boxed regions. Scale bar = 100µm. B. Total number of
activated microglia was counted in the cortex and a reduction in the number of activated
microglia was found in Pioglitazone treated animals compared to vehicle treated
animals. Compared with sham animals, Pioglitazone treated animals exhibited no
significant increase in activated microglia.
* p<0.05 by one-way ANOVA with SNK post-test.
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Discussion:
Previous reports from our group have shown that following TBI there is significant
impairment of cortical mitochondria which begins acutely and substantially damages the
mitochondria over the course of the first day following the injury (Pandya et al., 2007,
Gilmer et al., 2009, Pandya et al., 2009). Interventions that are capable of protecting
mitochondrial function following TBI have been demonstrated to reduce cortical damage
and behavioral impairment (Scheff and Sullivan, 1999, Sullivan et al., 2000c, Pandya et
al., 2007, Pandya et al., 2009). In the present studies, mitochondrial function was
analyzed one day following the injury. We chose this time point based on previous
experiments which have shown that at this time post-injury there is significant
mitochondrial dysfunction in our model of cortical impact injury (Pandya et al., 2009). We
found that with Pioglitazone treatment there are improvements in mitochondrial function
which are observed in the Complex-I dependant, Pyruvate/Malate-driven, rates of
oxygen consumption as well as the State III (ADP-present) and maximal (uncoupled)
respiration rates, a measure of electron transport capacity/reserve (Figure 4.1B). From
the mitochondrial experiments it can be concluded that animals treated with Pioglitazone
maintain more functional mitochondria which are capable of producing more ATP and
therefore providing the brain with the much needed energy source required for normal
function as well as post-injury protective and reparative mechanisms. The mitochondrial
data from these experiments also suggests that at least part of Pioglitazone’s ability to
improve mitochondrial function involves a direct effect on the mitochondria since a single
15 minute post injury injection only produced a non-significant trend towards improved
mitochondrial bioenergetics (Figure 4.1A) while a subsequent injection of Pioglitazone
one hour prior to analyzing the tissue resulted in a dramatic increase in mitochondrial
bioenergetic function (Figure 4.1B). Since the improvement in mitochondrial function was
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only observed after giving the second injection, the mitochondrial effect is most likely not
due to only an up regulation of protein expression. Previously published in vitro
experiments have shown that treatment with Pioglitazone can up regulate mitochondrial
electron transport proteins, however, these changes take at least two days to produce
significant increases in protein levels (Miglio et al., 2009). Up regulation of mitochondrial
protein expression is not likely the cause for the improvements in mitochondrial function
seen in these experiments after the first 24 hours of Pioglitazone treatment, especially
considering the rapid change in mitochondrial function observed one hour following the
second Pioglitazone treatment. In order to help in determining whether Pioglitazone has
a direct effect on mitochondrial function, future experiments should incorporate
modifications to the current treatment and testing paradigm. Similar to the testing
following the second injection of Pioglitazone at 24 hours post injury, further
experimentation should include analysis of mitochondrial function one hour following the
first 15 minute post injury injection. Since the majority of the Pioglitazone should be
metabolized from the body 25 hours after a single injection, the lack of a therapeutic
effect on mitochondrial function following the single injection paradigm could simply be
that the Pioglitazone is no longer in the system. Treatment with Pioglitazone will likely
produce even greater improvements in mitochondrial function at time points beyond 24
hours when significant increases in mitochondrial proteins are likely occur. The rapid
increase in mitochondrial function seen after the second injection of Pioglitazone may
involve the mitochondrial outer membrane bound protein MitoNEET. Previously it has
been shown that Pioglitazone binds to MitoNEET and stabilizes its conformational
structure (Paddock et al., 2007) and that knocking-out the MitoNEET protein results in
reductions in mitochondrial electron transport chain function (Wiley et al., 2007). In
addition to Pioglitazone’s ability to rapidly increase mitochondrial function as seen in
these studies, considering that PPAR agonist treatment leads to reductions in oxidative
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damage (Chen et al., 2007a, Yi et al., 2008) and inflammation (Besson et al., 2005,
Chen et al., 2007a, Park et al., 2007, Hyong et al., 2008, Kapadia et al., 2008) following
injury, Pioglitazone treatment will promote a less hostile cellular environment which will
lead to reductions in secondary injury cascades that cause further mitochondrial
dysfunction and propagate bioenergetic impairments.
To further understand the effects of Pioglitazone following TBI, we wanted to
determine if Pioglitazone was capable of reducing lesion volume and improving
cognition. PPARγ agonists, in particular Pioglitazone, have been examined for protective
properties in several models of CNS injury and disease (Sundararajan et al., 2006),
including spinal cord injury. Following spinal cord injury, Pioglitazone offers protection
against the induction of inflammatory genes, astrogliosis, and microgliosis even if
treatment is delayed for up to two hours after the injury (Park et al., 2007). The
neuroprotective actions of Pioglitazone may be a general characteristic of PPARγ
activation, as this phenomenon has been noted in other models of CNS injury. For
instance, Pioglitazone treatment in murine models of Parkinson's disease promoted
neuronal sparing within the substantia nigra (Breidert et al., 2002, Dehmer et al., 2004).
Potent neuroprotection of motor neurons was also induced by Pioglitazone in transgenic
mouse models of amyotrophic lateral sclerosis (Kiaei, 2008). Additionally, several
studies have detected enhanced neuroprotection and decreased lesion sizes in animal
models of stroke and intracerebral hemorrhage (Ou et al., 2006, Victor et al., 2006). To
determine if any measurable effect on cognition or lesion volume was the result of
activation of the PPARγ pathway, the selective PPARγ antagonist T0070907 was coadministered with Pioglitazone. It has previously been shown that following TBI the injury
causes cortical damage which correlates well with cognitive dysfunction as measured
using the MWM (Marklund et al., 2001). From these studies it was determined that
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Pioglitazone is capable preserving cognitive function, as determined by MWM
assessment. It was observed at 15 days post injury that animals treated with
Pioglitazone exhibited a decreased latency time and distance to the platform compared
to animals treated with either vehicle or animals treated with Pioglitazone and the
PPARγ antagonist T0070907 together (Figure 4.2). Since the PPARγ antagonist was
able to block the protective effects of Pioglitazone on MWM function, activation of the
PPARγ receptor is further implicated as a beneficial therapeutic strategy for TBI.
Additionally, treatment with Pioglitazone resulted in a reduction of the size of the cortical
lesion at 16 days post injury with the size of the cortical cavity being reduced from
5.09±0.73mm3 (vehicle treated animals) to 2.27±0.27mm3 (Pioglitazone treated animals)
(Figure 4.3). Similar to the MWM testing, administration of the PPARγ antagonist
T0070907 almost completely blocked the neuroprotective benefit of Pioglitazone on
sparing cortical tissue, indicating that activation of the PPARγ pathway is critical to
attenuating cortical tissue loss as well as cognitive deficits. As has been observed in
other CNS injury models, these studies show that following TBI Pioglitazone is capable
of reducing neuronal cell loss and improving behavioral outcomes.
It has been established that TBI is accompanied by a dramatic inflammatory
response, which escalates over the first week post-injury and is thought to contribute to
the secondary pathology of TBI. Multiple studies link agonism of PPARγ to the
attenuation of inflammation (Jiang et al., 1998, Ricote et al., 1998, Drew et al., 2006),
such that PPARγ activation influences the development and intensity of the inflammatory
response.

With

the

realization

that

inflammation

plays

a

role

in

several

neurodegenerative diseases, researchers have searched for a role of PPARγ in
neurodegeneration. PPARγ activation regulates inflammation by decreasing the
expression of a variety of pro-inflammatory genes such as COX-2, iNOS, and several
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cytokines (Jiang et al., 1998, Ricote et al., 1998, Kitamura et al., 1999, Bernardo et al.,
2000) that have all been associated with inflammation-induced neurodegeneration
(Banati et al., 1993, Przedborski et al., 1996, Minghetti and Levi, 1998, Liberatore et al.,
1999, Heneka et al., 2000, Arimoto and Bing, 2003, Vijitruth, 2006). Previously it has
been shown that Pioglitazone protects against intrastriatal lipopolysaccharide (LPS)induced neurodegeneration by suppressing the inflammatory response, reducing
oxidative damage and preventing mitochondrial dysfunction (Hunter et al., 2008, Xing et
al., 2008). Since evidence shows that PPARγ is expressed throughout the brain (Moreno
et al., 2004) in neurons (Braissant et al., 1996) and glia (Cullingford et al., 1998, Heneka
et al., 1999, Bernardo et al., 2000, Cristiano et al., 2001), it is possible that PPARγ
agonism will inhibit neuroinflammation and neurodegeneration in multiple injury and
disease states. Because of its wide range of potential therapeutic efficacy, several
clinical trials using synthetic PPAR agonists have begun for the treatment of diseases
involving aberrant or chronic immune/inflammatory responses (Pershadsingh et al.,
2004, Risner et al., 2006).
To further elucidate the benefits of Pioglitazone following TBI, tissue was
analyzed for assessment of inflammation following injury. As has been previously shown
for other PPARα (Chen et al., 2007a, Chen et al., 2008) and PPARγ (Yi et al., 2008)
agonists, treatment with Pioglitazone resulted in a significant reduction in inflammation
following TBI in the present study. Following treatment with Pioglitazone, reductions in
the number of activated microglia were observed in the area of the cortex adjacent to the
site of the cortical lesion (Figure 4.4). In contrast to our data indicating that the effect of
Pioglitazone on the cortical lesion and cognitive function is dependent on the PPARγ
receptor, treatment with the PPARγ antagonist along with Pioglitazone did not prevent
the reduction in activated microglia in these experiments. These studies indicate that
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Pioglitazone’s ability to reduce inflammation following TBI is not dependent upon PPARγ
receptor activation. Even though Pioglitazone is predominately a PPARγ agonist,
Pioglitazone has been shown to also activate the PPARα receptor (Sakamoto et al.,
2000). Considering that activation of the PPARα receptor has previously been shown to
reduce microglial activation (Xu et al., 2005) it is possible that Pioglitazone’s ability to
reduce inflammation following TBI can be through activation of the PPARα pathway.
Additionally, since mitochondrial dysfunction can lead to cell death and cause increases
in inflammation, it is expected that the protective effects of pioglitazone on mitochondrial
function (Figure 3.1B) are likely to lead to further reductions in post-injury increases in
inflammation. Regardless of the exact mechanism(s) by which Pioglitazone leads to
reductions in inflammation, the evidence from this study and studies in SCI (Park et al.,
2007) indicate that Pioglitazone treatment leads to significant reductions in inflammation
following injury. In order to further the understanding of how Pioglitazone leads to a
reduced inflammatory response following TBI, future experiments should seek to
elucidate the role of other PPAR receptors in pioglitazone’s neuroprotective effect. As
previously mentioned, since Pioglitazone can activate PPARα, further working utilizing
selective PPARα inhibitors or knock-out animals are needed to determine the role of the
pathway in pioglitazone’s ability to reduce inflammation. Since at this time only the
PPARγ pathways can be excluded from playing a role in the anti-inflammatory actions of
Pioglitazone it is unknown whether the effect is mediated by a different PPAR pathway
or a completely different mechanism.
These experiments are the first to show a therapeutic effect of Pioglitazone
following TBI and they fit well with what has been previous shown regarding the use of
PPAR agonists in CNS injury. As has been observed in SCI (McTigue et al., 2007),
Pioglitazone is capable of reducing the cortical lesion and improving behavioral outcome
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following injury. These experiments also produce similar findings to studies that have
utilized either PPARα or PPARγ agonists following TBI that produce reductions in
inflammation (Chen et al., 2007a, Yi et al., 2008), reduction in lesion volume (Yi et al.,
2008), and behavioral improvement (Chen et al., 2007a, Chen et al., 2008). This is the
first report to our knowledge of any PPAR agonist showing protection of mitochondrial
function following TBI. These experiments show that following TBI Pioglitazone is
capable of protecting mitochondria, reducing inflammation, minimizing the cortical lesion,
and improving cognitive function. Given the results of these experiments and considering
that Pioglitazone has been shown to have better BBB permeability than the other
PPAR agonist Rosiglitazone (Berger and Moller, 2002), as well as partially activate the
PPARα pathway (Sakamoto et al., 2000), which has been shown to be efficacious
following TBI (Chen et al., 2007a, Chen et al., 2008), we feel that Pioglitazone will be a
more effective treatment for TBI than other PPAR agonists previously utilized for the
treatment of TBI.
Even with the success of the current studies, further work is needed before
Pioglitazone should be considered for human clinical usage. Of significant important, the
current studies only utilized a single dose of Pioglitazone and began administration 15
minutes after the injury. Both a dose response study and a delayed administration study
are needed in order to properly plan a human trial and determine if administration can be
delayed longer than 15 minutes, which would be needed for nearly any human treatment
window. Additionally, given the heterogeneity of human TBI it would be beneficial if
Pioglitazone was tested in multiple different experimental TBI models. Though evidence
from other models and similar PPAR agonists suggest that Pioglitazone would be
effective for different types of TBIs without empirical evidence directly testing
Pioglitazone it is unknown whether it would have any effect or even be potentially

115

detrimental to specific pathological subtypes. Without testing Pioglitazone in humans it
will never be known whether or not it will be beneficial at treating human TBI. However,
in order to provide any future clinical trials with the best possible chance of success
much more research is needed regarding dosing and differences in efficacy with
different types of TBI pathology.

Copyright © Andrew David Sauerbeck 2011
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Chapter 5
Summary and conclusions

Further elucidating of the role of both toxins and treatments in traumatic brain
injury will help in understanding the pathology which occurs following neurological insults
and how to potentially intervene in order to minimize damage. Beyond just the direct and
acute deficits which have been shown to occur after traumatic brain injury (Sullivan et
al., 1999c, Sullivan et al., 2000a, Sullivan et al., 2000c, Sullivan et al., 2002, Sullivan et
al., 2003), a strong link has been shown between history of a brain injury and the
development of Parkinson’s disease later in life (Nayernouri, 1985, Bower et al., 2003).
Though TBI is linked to PD, it is currently unknown if traumatic brain injury alone is
capable of leading to Parkinson’s and evidence from both humans (Semchuk et al.,
1993, Carvey et al., 2006) and animals (Thiruchelvam et al., 2000a, Thiruchelvam et al.,
2000b, Thiruchelvam et al., 2002, Thiruchelvam et al., 2003, Ling et al., 2004a, Ling et
al., 2004b, Fei and Ethell, 2008) suggests that multifactorial paradigms may play a role
disease development.
Like many of the environmental toxins linked to the development of PD in
humans, trichloroethylene has been shown to produce neuropathology in animal studies
(Gash et al., 2008, Liu et al., 2010) and human investigation has indicated a link
between chronic TCE exposure and the development of PD (Gash et al., 2008). Studies
utilizing dual injury paradigms should help in further understanding the development of
PD in humans by attempting to mimic the complex history of exposures and insults
which a person would be exposed to during his/her life. Even with evidence from dual
injury models, much work is still needed to fully understand the complexities of disease
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development in humans since many factors have been shown to play a role in disease
development.
The studies presented here, utilizing trichloroethylene exposure followed by
traumatic brain injury, provide an initial indication that the two insults may in fact be
capable producing a dual injury phenotype. However, the model does not result in
changes which mimic severe human PD. Behavioral analysis revealed that only
following exposure to TCE and a moderate TBI was impairment with both the rotarod
and cylinder test was present (Figure 2.1). Though behavioral dysfunction was observed
it still remains unknown what the exact cause of the behavioral impairment is since
various CNS and non-CNS factors can play a role in these measurements. It was
hypothesized that following the dual injury there would be a much greater loss of
dopamine neurons in the substantia nigra and dopaminergic impairment in the striatum
than was observed in these studies. One month following the dual injury there was a
loss of tyrosine hydroxylase positive neurons in the substantia nigra but the cell loss was
only about 13-17% (Figure 2.2). Given evidence from humans (Riederer and Wuketich,
1976, Morrish et al., 1996), this level of cell loss should not be capable of producing
behavioral impairment independently which suggests a role for the brain injury, the dual
injury, or both in the behavioral impairment. Additionally, no observable changes were
observed in the striatal dopaminergic system one month following the dual injury (Figure
2.3) which indicates that excessive loss of dopaminergic fibers and specific synaptic
proteins has not occurred in this model. As expected for a moderate traumatic brain
injury, there was a persistent loss of cortical tissue following the injury which was not
affected by exposure to TCE (Figure 2.4). Mitochondrial impairment was observed in the
striatum following two week exposure to TCE, however, the level of impairment was
great enough with TCE alone that observing a dual injury affect was made nearly
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impossible (Figure 2.5). Further studies utilizing a 1 week exposure to TCE showed no
measurable decrease in mitochondrial function following either insult alone. However,
exposure to TCE for 1 week followed by a TBI resulted in a 50% reduction in Complex I
driven mitochondrial oxygen consumption. From the experiment utilizing the 1 week
exposure to TCE it is further concluded that TCE and TBI can interact in a dual injury
model and that the mitochondria play a pivotal role in the interaction.
Though the behavioral testing does not target a specific single pathway which the
neurological dysfunction can be said to originate from, the data still suggests that a dual
injury plays a role in the dysfunction. Neither exposure to TCE or TBI alone resulted in
any measurable functional impairment but when TCE and a moderate TBI were
combined together impairment did occur. Further experimentation is required to
elucidate the pathological mechanisms which lead to the functional impairment. Two
scenarios exist which could underlie the neurological changes which resulted in
functional changes. First, the two insults could affect the same brain region(s) and this
synergistic targeting could be responsible for the dysfunction. Second, the two insults
could affect different regions of the brain individually and the presence of neurological
dysfunction in these different brain regions may be the cause of the functional
impairment. The cortex, striatum, and substantia nigra have all been shown to have
some deficits in this model, some single insult based and some dual insult based, and
given that all three of these regions play a role in dopaminergic function (Figure 1.5) it
remains plausible that multiple brain regions may need to be affected in order for
functional impairment to occur in this model.
In addition to indicating the possibility of a dual injury mechanism, the
mitochondrial studies further support the notion that systemic exposure to TCE can
result in mitochondrial impairment in the brain. Even though previous work (Gash et al.,
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2008) resulted in a different regional profile for the mitochondrial impairment than the
present experiments, these studies utilized total purified mitochondria while previous
work utilized synaptosomes for the mitochondrial analysis. It has been previously
established that significant differences exist between synaptic and non-synaptic
mitochondria in the brain (Davey et al., 1997, Brown et al., 2006, Naga et al., 2007) and
this difference may underlie the seemingly conflicting results. Regardless, the analysis of
the striatal mitochondria revealed a very significant impairment of mitochondrial function
which was present in both groups exposed to TCE for 2 weeks (Figure 2.5).
In order to further understand the ability for TCE to produce regionally different
mitochondrial impairment, it is important to understand regional differences in
mitochondrial function and susceptibility to toxins. Previous animal studies (Ryder, 1980,
Sims, 1991, Davey et al., 1997), and work utilizing animals exposed to trichloroethylene
(Gash et al., 2008, Liu et al., 2010) or other mitochondrial toxins (Beal et al., 1993,
Mirandola et al., 2010) have shown that regional differences in mitochondrial function
and toxin susceptibility do exist. However, the reasons for the regional differences in
mitochondrial dysfunction remain elusive. The present studies with naïve mitochondria
suggest that with the exception of the cerebellum no major differences exist in
mitochondria throughout the cortex, hippocampus, and striatum with respect to Complex
I and Complex II dependent function (Figure 3.1). It has been established in vivo that
different brain regions have different metabolic demands (Kennedy et al., 1976, WongRiley, 1979) and neuronal activity affects the amount of mitochondria and mitochondrial
proteins (Tieman, 1985, Nie and Wong-Riley, 1996) and these differences likely have
little to do with the function of individual mitochondria. When the amount of mitochondria
is controlled for by normalizing to protein content, regional differences in mitochondrial
function are not strikingly different. This finding extends to mitochondrial Complex I and
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Complex II inhibitors were no differences are seen in the inhibition of enzyme activity
(Figure 3.2) and only small differences in oxygen consumption are seen at low
concentrations, 10pM and 100pM, of rotenone (Figure 3.3). These findings suggest that
the regional differences in mitochondrial dysfunction shown following exposure to TCE
may not be the result of regionally different individual mitochondria. Mirandola et al.
suggested that the regional differences in 3-NP induced changes in the susceptibility to
mitochondrial permeability transition may be the result of regional differences in the
environment which the mitochondria exist in (Mirandola et al., 2010). Interestingly,
Mirandola found the striatum to be the region most susceptible to 3-NP inhibition
(Mirandola et al., 2010) and this is the same region most affected by TCE in these
studies. Given the lack of overt regional differences in basal function and susceptibility to
inhibitors in purified naïve mitochondria from the cortex, hippocampus, and striatum the
most likely conclusion is that the mitochondria are in fact functionally very similar across
brain regions. Given that regional differences in mitochondrial function following
exposure to TCE do exist, but the affected and non-affected mitochondria are likely the
same, interventions which target the pathways responsible for making one region more
susceptible than another region may be effective at ameliorating regionally specific
deficits.
In addition to the possibility to target pathways which may make a specific brain
region more susceptible to a systemic toxin, therapeutically targeting one part of a dual
injury insult may provide the ability avoid or minimize the occurrence of functional
impairment. Given that traumatic brain injury plays a role in our dual injury model,
developing effective therapeutics to treat the brain injury is likely to provide two benefits.
First, if an effective TBI therapeutic is developed TBI patients should receive benefit
regardless of the presence of an additional insult. Second, if the patient already has an
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initial insult or sustains a second insult later in life, effectively treating the TBI may
prevent the development of dual insult based pathology.
The studies utilizing Pioglitazone reveal that not only is the drug capable of
minimizing some of the mitochondrial dysfunction, the effect is likely to involve a nonPPARγ mediated pathway (Figure 3.1). Additionally, cognitive testing showed that
animals treated with Pioglitazone were not significantly different than sham animals
while vehicle treated animals were significantly different (Figure 3.2). The behavioral
effects suggest that Pioglitazone does provide protection against cognitive impairment
and finding an optimal dosing strategy should provide more robust cognitive benefits.
Analysis of cortical tissue loss and increases in the number of activated microglia show
that Pioglitazone is able to reduce both of these endpoints following TBI even though
tissue loss was PPARγ dependent while microglial activation was not. This initial report
of the therapeutic benefit of Pioglitazone will hopefully lead to further work which can
help human patients who sustain a brain injury. Further work should be done to better
understand the optimal dosing of the drug but the potential for a therapeutic benefit has
now been shown with these studies.
The findings of the three separate projects come together to suggest of role for
toxin, treatments, and brain regions following traumatic brain injury and dual injury
models. The overall conclusion is that TCE and TBI are able to interact and produce
behavioral dysfunction and a loss of TH-positive neurons in the substantia nigra,
however, more work needs to be done refining the experimental model to understand
the impact these findings have on Parkinson’s disease. The mitochondrial impairment in
the striatum following TCE exposure is likely the result of regional differences in the
cellular environment within the striatum which these mitochondria exist. The conclusions
about the regional TCE effect are made possible because exposure to the complex I
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inhibitor rotenone resulted in only small regional differences in mitochondrial oxygen
consumption across the brain, specifically at low concentrations of 10pM and 100pM.
Furthermore, it is hypothesized that treating a single insult in a dual injury paradigm will
prevent the dual injury phenotype, and so effective therapeutics for one of the single
insults are necessary to test this hypothesis. Given that Pioglitazone can attenuate
pathology following TBI, and the role TBI plays in this dual injury model, future work may
show if Pioglitazone is effective at attenuating deficits observed with this dual injury. The
studies presented here should assist future research in understanding how toxins and
treatments may affect traumatic brain injury and the role or lack thereof in regional
mitochondrial function in affecting outcome.

Copyright © Andrew David Sauerbeck 2011
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